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3Abstract
Epigenetic changes may contribute substantially to risks of diseases of ageing. Previous studies 
reported seven methylation variable positions (MVPs) robustly associated with incident type 2 
diabetes mellitus (T2DM). However, their causal roles in T2DM are unclear. In an incident T2DM 
case-cohort study nested within the population-based EPIC-Norfolk cohort, we used whole blood 
DNA collected at baseline, up to 11 years before T2DM onset to investigate the role of methylation in 
the aetiology of T2DM. We identified 15 novel MVPs with robust associations with incident T2DM, 
and robustly confirmed three MVPs identified previously (near to TXNIP, ABCG1 and SREBF1). All 
18 MVPs showed directionally consistent associations with incident and prevalent T2DM in 
independent studies. Further conditional analyses suggested that the identified epigenetic signals 
appear related to T2DM via glucose and obesity-related pathways acting before the collection of 
baseline samples. We integrated genome-wide genetic data to identify methylation-associated 
quantitative trait loci robustly associated with 16 of the 18 MVPs, and found one MVP, cg00574958 
at CPT1A, with a possible direct causal role on T2DM.  None of the implicated genes was previously 
highlighted by genetic association studies, suggesting that DNA methylation studies may reveal novel 
biological mechanisms involved in tissue responses to glycemia. 
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4Introduction
Type 2 diabetes mellitus (T2DM) is a major and increasing public health problem. Genome-wide 
studies have identified more than 240 genetic variants1 that are robustly associated with T2DM. 
However, these only explain a minor portion of T2DM susceptibility variance2,3. Environmental 
factors, including diet and physical activity, and also early life factors during fetal and early postnatal 
development are reported to contribute to the aetiology of T2DM. Epigenetic variation can occur as a 
result of genetic and/or environmental factors4. DNA methylation (DNAm) at cytosine-guanine 
dinucleotides (CpG sites) is the most commonly studied epigenetic mechanism to date, due to its role 
in expression regulation and available assays to quantify DNAm intensity at multiple sites across the 
epigenome that are applicable to large scale studies. Unlike genotypic variation, DNAm intensity 
patterns are liable to change over time, with age or following disease or other exposure, and therefore 
disease-associated changes may be either causal or consequential5.  
Previous epigenome-wide association studies (EWAS) have identified seven methylation variable 
positions (MVPs) that are significantly associated (P<1·0x10-7) with incident T2DM6,7. However, the 
causal role of those markers in T2DM is unclear. Here, we aimed to elucidate DNAm determinants of 
T2DM by performing an EWAS for incident T2DM in the European Prospective Investigation into 
Cancer and Nutrition (EPIC)-Norfolk study8.  By further integrating genome-wide genetic array data, 
we aimed to identify methylation quantitative trait loci (methQTLs) for any T2DM-associated MVPs, 
in order to assess the likely causal role of DNAm markers on T2DM through Mendelian 
randomization analyses9.
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5Methods
Cohort descriptions
The discovery phase EWAS was undertaken in an incident T2DM case-cohort study nested within the 
EPIC-Norfolk study8, a prospective cohort study that recruited 25,639 individuals aged between 40-79 
years at baseline in 1993-1997. The cohort was representative of the general population of England 
and Wales for age, sex, anthropometric measures, blood pressure and serum lipids, but differed in that 
99.7% of the cohort were of European descent. We defined a random sub-cohort of the whole EPIC-
Norfolk study population excluding known prevalent cases of diabetes at baseline using the same 
definitions as used in the InterAct project10 who had available genotype data. Incident T2DM cases 
were ascertained from multiple sources: two follow-up health and lifestyle questionnaires providing 
self-reported information on doctor-diagnosed diabetes or medications; medications brought to the 
second clinical exam; and medical record linkage. Record linkage to external sources included the 
listing of any EPIC-Norfolk participant in the general practice diabetes register, local hospital diabetes 
register, hospital admissions data with screening for diabetes-related admissions, and Office of 
National Statistics mortality data with coding for diabetes. Participants who self-reported a history of 
diabetes which could not be confirmed against any other sources were not considered as confirmed 
cases. Follow-up was censored at date of diagnosis of T2DM, 31 July 2006, or date of death, 
whichever came first. By definition in case-cohort design, there are cases within- and outside- the 
random sub-cohort but for the purposes of this analysis, we considered them in the incident case set 
only, with non-cases forming the comparison group. BMI and HbA1c levels were measured for each 
participant at baseline (Table 1). All participants in the EPIC-Norfolk study gave signed informed 
consent and the study was approved by the Local Research Ethics Committee.
Confirmation of top signals from the discovery EWAS was sought in two further studies. The London 
Life Sciences Prospective Population (LOLIPOP) study is a prospective population study of Indian 
Asian (N=17,606) and European (N=7,766) individuals, recruited at age 35–75 years from the lists of 
58 family doctors in west London, UK, between May 1, 2002, and September 12, 2008. Indian Asians 
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6had all four grandparents born on the Indian subcontinent (India, Pakistan, Sri Lanka, or Bangladesh). 
The LOLIPOP study is approved by the National Research Ethics Service (07/H0712/150) and all 
participants gave written informed consent at enrolment. The LOLIPOP nested case-control study of 
incident T2DM has been previously described6. Briefly, at follow-up, on Dec 31, 2013, individuals 
with T2DM were identified by primary care electronic health records and structured queries. 
Participants with incident T2DM were defined as those who did not have T2DM at baseline, but who 
developed the disease during follow-up. Controls were identified from a random subset of 7640 
participants who attended a clinical assessment of fasting blood glucose concentration and HbA1c and 
questionnaire assessment between Jan 11, 2010, and Dec 31, 2013.
The Framingham Heart Study (FHS) is a community-based longitudinal study of participants living in 
and near Framingham, MA, at the start of the study in 194811. The Offspring cohort comprised the 
children and spouses of the original FHS participants, as described previously12. Briefly, enrolment 
for the Offspring cohort began in 1971 (N = 5,124), and in-person evaluations occurred approximately 
every 4 to 8 years thereafter. The current analysis was limited to participants from the Offspring 
cohort who survived until the eighth examination cycle (2005 to 2008) and consented to genetics 
research. DNAm data of peripheral blood samples collected at the eighth examination cycle were 
available in 2,741 participants. Prevalent T2DM was defined as having fasting glucose  ≥ 7 mmol/L 
or as reporting taking T2DM medication at any examination cycle, up to the eighth examination.  All 
participants provided written informed consent at the time of each examination visit. The study 
protocol was approved by the Institutional Review Board at Boston University Medical Center 
(Boston, MA, USA).
Methylation array profiling
In all studies, DNAm intensity was measured using the Illumina HumanMethylation450 array (12-
sample array for FHS, 96-sample array for EPIC-Norfolk and LOLIPOP).  Bisulfite conversion of 
DNA was performed using the EZ DNA methylation kit (Zymo Research, Orange, CA, USA).
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7For 1,378 EPIC-Norfolk participants, DNAm was measured in DNA extracted from whole blood 
samples collected at baseline. Converted DNA was assayed by PCR (Polymerase Chain Reaction) and 
gel electrophoresis. Each 96 well DNA sample plate contained two duplicate samples. The average 
correlation between the duplicate samples was 98%.
In LOLIPOP, DNAm was measured among the first 1,074 Indian Asian participants with incident 
T2DM and 1,590 matched Indian Asian controls. Controls were matched to cases by age (5-year 
groups) and sex. DNAm was quantified in the baseline DNA samples collected at study enrolment. 
Samples were analysed in random order, masked to case-control status. 
In FHS, peripheral blood samples were collected at the eighth examination (2005 to 2008). Genomic 
DNA was extracted from buffy coat using the Gentra Puregene DNA extraction kit (Qiagen). 
Bisulphite converted DNA samples were hybridised to the 12 sample Illumina HumanMethylation450 
array using the Infinium HD Methylation protocol and Tecan robotics (Illumina, San Diego, CA, 
USA). DNAm quantification was conducted in two laboratory batches. 
EWAS quality control and normalisation
In EPIC-Norfolk, epigenome-wide DNAm data were analysed in R (version 3.2.2).  Initial quality 
control was performed as recommended by the array manufacturer; methylation intensity values were 
corrected using the Illumina Background Correction algorithm as implemented in minfi13, methylation 
intensities with a detection P-value ≥0·01 were set to ‘missing’ and methylation intensity beta values 
were calculated for each methylation marker per sample. For duplicate samples, the sample with the 
lower CpG detection percentage was excluded.  
Sample call rates were calculated as the proportion of missing data in each sample, by autosomal, X 
and Y chromosomes. For the autosomal data, 77 samples with a call rate ≤0·99 were excluded. All 
samples passed the call rate threshold on the X chromosome. For the Y chromosome, seven male 
samples that did not pass the call-rate and two further female samples were excluded.  Distributions of 
methylation intensities were also inspected by autosomal and sex chromosomes, and separately in 
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8females and males leading to the exclusion of two additional samples that had an unusual distribution 
of methylation intensities. After those quality control procedures, data on 1,290 samples remained. All 
further downstream analyses were restricted to autosomal methylation markers. 
Marker call rates were calculated as the proportion of missing data at each CpG site.  8,775 CpGs 
with a call rate ≤0·95 were excluded. The R package ENmix14 was used to identify CpG sites with 
multimodal distributions of methylation intensity, which typically arise from technical artefacts; 3,295 
such CpG sites were excluded. A further 18,874 CpG sites with probes previously identified as 
mapping to more than one genomic location were also excluded15. 
To ensure reliability of the data, filtering on sample and marker call rates were repeated until all 
samples and all markers passed their respective call rate thresholds. After excluding prevalent T2DM 
cases at baseline, the final dataset comprised 1,264 samples (563 incident T2D cases, including 22 
cases from the subcohort, and 701 non-cases) with methylation intensities at 442,920 autosomal CpG 
sites. Quantile normalisation of methylation intensity beta values was applied separately to the 
different sub-groups of markers based on colour channel, probe type and methylated/unmethylated 
subtypes as proposed by Lehne et al.16  
In LOLIPOP, DNAm data were analysed in R (version 2·15) using minfi13 and other R scripts. Marker 
intensities were normalised by quantile normalisation as previously described6.
In FHS, DNAm data were normalized using the DASEN methodology implemented in the 
wateRmelon package17. Sample exclusion criteria included poor SNP matching of control positions, 
missing rate >1%, outliers from multi-dimensional scaling, and sex mismatch. Probes were excluded 
if missing rate >20%. Data from laboratory batches were pooled leaving up to 2,635 samples and 
443,304 CpG probes for analysis. Additional information on DNAm, normalization and quality 
control is available in Asbeykian et al.18. Differences in DNAm data generation, quality control and 
statistical models are summarised in Table S1.
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In EPIC-Norfolk, to identify MVPs associated with incident T2DM, we performed a logistic 
regression model for each methylation marker with incident T2DM status, adjusted for age, sex, 
estimated cell counts, and sample plate using the EWAC pipeline. A conservative multiple test 
corrected P-value threshold was applied (P<1x10-7). Different methylation profiles have been 
observed between the different cell types in whole blood19 and blood-based profile of DNAm was 
shown to predict the underlying distribution of cell types20. To correct for cell composition 
variability21, first the proportions of different cell types (CD4+, CD8+ T cell subtypes, natural killer 
cells, monocytes, granulocytes and B cells) were estimated from DNAm data using the algorithm 
described by Houseman et al.22 as implemented in the R package minfi13. These cell count estimates 
were then used as covariates in the epigenome-wide regression models for incident T2DM.  
We used STRING23 to perform gene-set enrichment on the significant genes associated with the 18 
significant MVPs identified in the EWAS. We also performed a modified version of the 
MAGENTA24 pipeline to identify the pathways associated with genes at the loci of the significant 
MVPs. Since MAGENTA uses SNP data to identify loci, we assigned to each CpG a “nearest SNP” 
based on HapMap3 data and using build 36 positions for both the CpG site and the SNPs (average 
distance to the nearest SNP=4,175 base pairs, IQR=1,375-4,859; 1,707 out of 466,039 CpGs were not 
assigned a SNP). In effect, rather than using a SNP P-value to rank genes to assess enrichment we use 
the P-value from the methylation site to run MAGENTA.  
For LOLIPOP, an epigenome-wide association of DNAm was performed in Indian Asians with 
incident T2DM who were identified from the 8-year follow-up of the study. Differential white blood 
cell (lymphocyte, monocyte, and granulocyte) count was available for all participants, and 
epigenome-wide methylation scores were used to impute a further four lymphocyte subsets (CD4, 
CD8, natural killer, and B cells). Principal components analysis was performed to quantify latent 
structure in the data, including batch effects. Associations between incident T2DM and the 18 
significant MVPs identified in EPIC-Norfolk were tested using logistic regression including intensity 
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values from Infinium 450K assay control probes, bisulfite conversion batch, measured white cells and 
imputed white cell subsets, and the first five principal components as covariates. Association results 
were corrected for the genomic control inflation factor. For testing the predictive ability of the 18 
markers for incident T2DM, univariate logistic regressions were run for each of the 18 markers to 
obtain individual effect sizes (betas) for incident T2DM. A weighted methylation risk score (MRS) 
was subsequently calculated from these betas, and receiver operating curve (ROC) analyses were 
performed to provide estimates for area under the curve (AUC).
In FHS, association between each identified MVP (associated with incident T2DM in EPIC-Norfolk) 
was tested for association with prevalent diabetes and glycemic traits (fasting glucose, fasting insulin, 
HbA1c). The analysis of glycemic traits included only non-diabetic individuals. Fasting insulin was 
natural log-transformed. Random effects statistical models were used to analyze the data to account 
for sibling correlation and included adjustments for age, sex, white blood cell counts, technical 
covariates, batch effects and BMI, with DNAm as the dependent variable.
We also examined each T2DM-associated MVP for additional cross-sectional association with Type 1 
diabetes (T1DM) in an earlier EWAS of 52 monozygous twin pairs discordant for T1DM, in cell-
sorted peripheral blood mononuclear cells (monocytes, B cells or T cells)25 . As T2DM and T1DM 
have largely differing aetiologies, MVPs that are consistently associated with both outcomes may 
indicate metabolic effects of diabetes on DNAm.
Other tissues
The relevance of changes in DNAm intensity in whole blood to other tissues was tested by analyzing 
genome-wide DNAm data, generated using the Illumina HumanMethylation450 array, from human 
liver, adipose tissue, and skeletal muscle, as previously published26. Human liver DNAm data were 
from participants of the Kuopio Obesity Surgery Study (KOBS); 35 with T2D and 60 without27. Data 
on adipose tissue (14 pairs),  skeletal muscle (17 pairs) and blood (19 pairs) were from monozygotic 
twins discordant for T2DM26,28,29. Adipose tissue and skeletal muscle from the same individual were 
available for most of these twin pairs (16 pairs in blood/muscle 14 pairs in blood/fat); concordance in 
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DNAm intensity across these tissues was tested for each highlighted MVP by Spearman correlation 
tests. We further tested cross-tissue correlations in DNAm at T2DM-associated MVPs between blood 
and other tissues of relevance to T2DM aetiology, liver and pancreas, in publicly available 450K 
methylation array data from 6 cadavers sampled within 12 hours post-mortem (mean age 65.5 years, 
SD = 7.2)30 . 
Mendelian randomization analyses 
We performed bi-directional Mendelian randomization analyses to test whether any T2DM-associated 
MVP had a causal effect on T2DM or are a consequence of metabolic differences that had originated 
before the baseline measurement in this study. To predict the causal effect of each of T2DM-
associated MVP on T2DM, methQTLs associated with each MVP (FDR <0·05) in whole blood in 
3,841 adults of European descent were identified using the BIOS QTL browser31. To run Mendelian 
randomization analyses, the Z-score for each methQTL was converted to beta and standard error 
using the formulas32:
𝑏𝑒𝑡𝑎 =  𝑍𝑁 × 2 × 𝑀𝐴𝐹 × (1 ― 𝑀𝐴𝐹)
𝑆𝐸 = 1𝑁 × 2 × 𝑀𝐴𝐹 × (1 ― 𝑀𝐴𝐹)
where N is the sample size and MAF is the minor allele frequency. We then tested these methQTLs in 
Mendelian randomization analyses9 for T2DM. Genetic associations with T2DM were estimated in 
69,677 cases and 551,081 controls from the UK Biobank study33, the EPIC-InterAct study10 and the 
DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium2. A summary statistics 
method (inverse variance weighted, IVW) that combines all the SNPs for each MVP as a genetic 
instrument was used to predict the effect of that MVP on T2DM34. To ensure that the instruments are 
independent, clumping was performed. MR-Egger regression was also used to assess the sensitivity of 
the results to violations of Mendelian randomization assumptions. Mendelian randomization analyses 
were run using the R package TwoSampleMR35.
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For the reverse direction causal assessment, we tested SNPs with previously reported associations 
with T2DM2 or related metabolic phenotypes (BMI36, fasting glucose37, 2-hour glucose38, fasting 
insulin39, fasting insulin adjusted for BMI37, insulin resistance40, insulin secretion41 and waist-hip-ratio 
adjusted for BMI42) to test whether these traits have causal effects on methylation intensity at any 
T2DM-associated MVP. We used summary statistics methods (IVW and Egger’s tests) that combine 
all the SNPs for each trait as a genetic instrument to predict the effect of that trait on each T2DM-
associated MVP34 in the cohort control samples of the EPIC-Norfolk (N=613) in whom genotype data 
were generated using the Affymetrix Axiom UK Biobank chip. All genotypes passed standard QC 
criteria as specified by the Affymetrix Best Practices pipeline and SNPs with MAF<5% in this sample 
were excluded.  
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, 
or writing of the report. AC, FD, JRBP, NJW and KKO had full access to all of the data in the study 
and AC and KKO had final responsibility for the decision to submit for publication.
RESULTS
MVPs associated with incident T2DM 
In the EPIC-Norfolk study, we identified 18 MVPs that are associated with incident T2DM at 
P<1x10-7, including 15 novel signals (Table 2). None of these was reported to have a SNP on the 
target CpG15. The two strongest associations were the previously reported signals at TXNIP 
(cg19693031; P=2.7x10-21), ABCG1 (cg06500161; P=6.4×10-14)6,7. We confirmed a third previously 
reported signal at SREBF1 (cg11024682; P=6.0x10-10), and provide supportive evidence for an 
additional signal at PROC (cg09152259; P=4.2x10-4) that had previously not been considered to be 
true due to lack of replication in Europeans (Table S2). 
We sought confirmation of the top 18 MVPs in data on 1,074 incident T2DM cases and 1,590 control 
samples from the LOLIPOP study and in cross-sectional data from FHS (403 with prevalent T2DM 
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and 2,204 controls) (Table 3). All 18 MVPs showed directionally consistent associations with 
incident T2DM (14 at P<0·05) and prevalent T2DM (16 at P<0·05). 
Novel MVPs associated with incident T2DM include cg14476101 (P=2·8x10-10), located in the gene 
body of PHGDH which encodes phosphoglycerate dehydrogenase, an enzyme involved the synthesis 
of L-serine and other amino acids, and cg00574958 (P=5.2x10-9) in the 5'UTR of CPT1A which 
encodes an enzyme that initiates mitochondrial oxidation of long-chain fatty acids (Table S11). Four 
of the 18 MVPs were located within solute carrier family genes (SLC1A5, SLC43A1, SLC9A1 and 
SLC9A3R1), which encode plasma membrane proteins that regulate cell transport of amino acids and 
other metabolites. 
To systematically explore the biological pathways implicated by T2DM-associated methylation 
signals, we first tested the 18 MVPs for gene set enrichment using STRING and identified significant 
enrichment for three pathways: “positive regulation of cholesterol biosynthetic process” (indicated by 
MVPs at ABCG1, SREBF1 and POR), “carnitine metabolic process” (indicated by CPT1A and POR) 
and “AMPK signalling” (indicated by PFKFB3, CPT1A and SREBF1). We then tested the full EWAS 
dataset in a modified MAGENTA pipeline and identified significant enrichment for T2DM-associated 
methylation signals in 10 pathways (Table S4), including “insulin receptor signalling”, “IGF-1 
signalling”, “Erythropoietin signalling”, “JAK signalling” and “Integrin signalling”. 
MVPs associated with glycemic traits 
In non-diabetic control FHS samples, all 18 T2DM-associated MVPs showed directionally concordant 
associations with fasting glucose, fasting insulin levels and BMI, and 16 of the 18 MVPs showed 
directionally concordant associations with HbA1c (Table S5). In additional conditional models in the 
EPIC-Norfolk discovery sample, the associations between all individual 18 MVPs with incident 
T2DM were markedly attenuated when models were further adjusted for baseline BMI and HbA1c 
(median attenuation 49%, Table S3), indicating that these DNAm intensity changes largely reflect 
baseline differences between future incident T2DM cases and other cohort participants.
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Furthermore, among 52 monozygous twin pairs discordant for Type 1 diabetes (T1DM), 7 of the 18 
T2DM-associated MVPs showed cross-sectional differences in DNAm intensity in peripheral white 
blood cells (monocytes, B cells or T cells) between the T1DM-affected and unaffected twin, 
consistent with an effect of glycemia on DNAm intensity (at TXNIP, SLC9A3R1, SREBF1, CPT1A, 
C7orf50, PFKFB3 and cg08309687) (Table S6).
Relevance of whole blood MVPs to other tissues
To explore the possible relevance of changes in DNAm intensity in whole blood to other tissues, 
relevant to T2DM pathogenesis, we examined these 18 MVPs in liver, adipose tissue, and skeletal 
muscle from individuals with and without T2DM. Nominal associations (P<0.05) were found with 
only our 2 strongest whole blood MVP signals: cg06500161 at ABCG1 in adipose tissue (as 
previously published26 and cg19693031 at TXNIP in skeletal muscle (Table 4). Furthermore, at 12 of 
the 18 MVPs there was evidence for a positive correlation in DNAm intensity between whole blood 
and liver, pancreas, adipose tissue or muscle (Table S7).
Causal effects on T2DM
To investigate the potential causal effects of the 18 T2DM-associated MVPs, we used the BIOS QTL 
browser31 to identify methQTLs (genetic sequence variants) that are robustly associated (at P<5x10-8) 
with DNAm intensity at any of the 18 MVPs. We found 54 methQTLs (33 cis, 21 trans) each 
associated with one of 16 MVPs (Table S8).  We then used these methQTLs as instrumental variables 
in Mendelian randomization analyses, based on aggregated publicly-available GWAS data in 69,677 
T2DM cases and 551,081 controls (DIAGRAM2, UK Biobank33 and EPIC-InterAct10). Only one of 
the 16 T2DM-associated MVPs with an identified methQTL showed nominal evidence for a direct 
causal association with T2DM, cg00574958 at CPT1A (P=0.01), however, for other MVPs the 
genetic-predicted effects overlapped with the observed effects in the LOLIPOP study (Figure 1, 
Table S9).  
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We performed reverse direction causal analyses, to identify causal effects of BMI and glycemic traits 
on methylation intensity at the 18 MVPs. Among non-T2DM participants in EPIC-Norfolk (N=613), 
none of the genetic instruments for the tested glycemic or metabolic traits (T2DM, BMI, fasting 
glucose, 2-hour glucose, fasting insulin, fasting insulin adjusted for BMI, insulin resistance, insulin 
secretion and waist-hip-ratio adjusted for BMI) showed a consistent association with any of the 18 
T2DM-associated MVPs (Table S10).
Prediction of T2DM
In the LOLIPOP study sample, which was independent of the discovery EWAS, the top 18 T2DM-
associated MVPs in aggregate showed no predictive ability for incident T2DM (AUC=0·53). 
Furthermore, the addition of these 18 MVPs did not improve on a prediction model based on other 
baseline phenotypes (BMI, HbA1c, age, sex: AUC=0·761; BMI, HbA1c, age, sex, plus 18 MVPs: 
AUC=0·762).   
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Discussion
In this prospective study, we substantially increased the number of MVPs in whole blood that are 
robustly associated with incident T2DM. Associations for 17 of the 18 MVPs were confirmed with 
either incident or prevalent T2DM in two independent studies, which indicates the consistency of 
T2DM-associated whole blood DNAm intensity changes across different settings and ethnicities. 
Genetic causal modelling identified evidence to support a causal effect of DNAm on T2DM at one of 
these MVPs, cg00574958 at CPT1A.  
The prospective designs of the EPIC-Norfolk and LOLIPOP studies aimed to identify MVPs that 
precede the development of T2DM. However, the identified T2DM-associated DNAm intensity 
changes were largely attenuated by adjustment for differences in BMI and glycemia that had 
developed prior to the baseline measurement in the prospective studies. Our Mendelian randomization 
analyses failed to find evidence for direct causal effects for the majority of T2DM-associated, as 
indicated by no detectable genetic-predicted effect of DNAm intensity on T2DM, and a wide 
discordance between the observed and genetic-predicted effects. Conversely, overlap between EWAS 
signals for T2DM and T1DM are consistent with effects of glycemia on DNAm intensity for at least 7 
of the 18 T2DM-associated MVPs.
Whether or not they show directly causal associations, these novel and consistent T2DM-associated 
MVPs are highly informative with regard to implicated genes and biological pathways. Notably, none 
of the genes implicated by this EWAS was previously identified by genetic variant association 
studies. This stark difference may suggest that T2DM-associated DNAm intensity changes may reveal 
novel biological mechanisms involved in tissue responses to glycemia rather than in the pathogenesis 
of insulin resistance or insulin secretion, which are implicated by those genetic studies. The highest 
signal, cg19693031 which lies on TXNIP, is also the most significant observation in other T2DM 
EWAS studies6,7. Phosphoglycerate dehydrogenase (PHGDH) catalyzes the first and rate-limiting step 
in glucose-derived serine synthesis and may indicate consequent purine and deoxythymidine 
nucleotide synthesis in response to hyperglycemia and potential tissue proliferative responses43.  
Functional variation in carnitine palmitoyltransferase 1 (CPT1A) regulates the composition of 
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circulating polyunsaturated n-3 fatty acids and docosahexaoenic acid44, is reported to activate lipolysis 
and mitochondrial activity in brown fat45,46, and to maintain pancreatic islet secretion of the principal 
hyperglycemic hormone, glucagon47. Solute carrier family members are sodium-dependent membrane 
transporters that regulate intracellular cell pH, cell volume, and other cellular events such as adhesion, 
migration, and proliferation, and also contribute to systemic homeostasis of fluid volume, acid-base 
balance and electrolytes. Specifically, SLC9A3R1 (NHERF1) binds to PTEN to activate the PI3 
kinase signaling cascade involved in cell survival, growth, proliferation48, and is a key component of 
insulin and IGF-1 signalling pathways that we found enriched for T2DM EWAS associations. These 
highlighted pathways could potentially contribute to the pathogenesis of micro- and macro-vascular 
complications of hyperglycemia. PFBK3, a regulator of glycolysis and insulin signalling in mice, was 
recently highlighted by a SNP association with late onset autoimmune diabetes, and we here provide 
independent evidence to support its role in human glucose regulation49.
We recognize a number of limitations of our study.  Both of the prospective study samples displayed 
large differences in baseline glycemia and BMI between incident T2DM cases and non-cases. This 
nested prospective study design aimed to identify interactions between genetic factors and baseline 
lifestyle factors measured prior to the development of clinically-diagnosed T2DM10. Since it is 
impossible to develop T2DM except by passing through a phase of non-diabetic hyperglycemia, it is 
inevitable that people who go on to get incident diabetes in a cohort study will have raised glucose 
levels at baseline if follow up is of short or medium duration. Future studies that have samples stored 
many years prior to disease onset would be required to identify when in the development of diabetes 
the T2DM-MVP associations become apparent. Secondly, our assessments of other, non-blood, 
tissues were limited in the range of tissues and numbers of samples available. Despite concordant 
changes in DNAm intensity between whole blood and various tissues relevant to T2DM pathogenesis 
at 12 of the 18 T2DM-associated MVPs, nominal differences in DNAm were found only for our 
strongest two MVPs, which suggest that larger study samples are needed. We recognize that whole 
blood is not a tissue of interest to the pathogenesis of T2DM, however current, and most likely future, 
large-scale EWAS are confined to such samples, and functional insights will depend on follow-up of 
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whole blood signals in other tissues50,51. The same issue of appropriate tissue of interest limits our 
genetic modelling approach, which identified genetic markers of DNAm intensity in peripheral blood. 
Furthermore, the sample size for this approach (N=3,841 in BIOS QTL31 and N=613 in the EPIC-
Norfolk cohort control group) is relatively small compared to data on QTLs for gene expression in 
peripheral blood (N=8,086 in Westra et al.52). Hence, we found only nominal evidence for a causal 
effect of DNAm at only one of the 18 T2DM-associated MVPs, at CPT1A, and for several MVPs the 
genetic-predicted effects were overlapping with the observed effects. Similarly, a recent large EWAS 
for BMI found a causal role of methylation at only one MVP (cg26663590 at NFATC2IP)53. There are 
various possible conceptualisations of the functional interplay between SNP, MVP and T2D, which 
provide alternative explanations other than SNP-to-DNAm-to-T2D54, but they do not limit the 
statistical detection of apparent causal signals. Future, larger reference data on QTLs for DNAm 
intensity in whole blood are being generated (GoDMC), which will allow more powerful tests for 
causality, although their relevance to DNAm in tissues of interest remains an important question. 
Finally, the determinants of the identified T2DM-associated MVPs remain unknown. Again, larger 
reference panels of GWAS and DNAm array data, as well as new methods to integrate findings across 
multiple methQTLs for each MVP, will inform future causal analyses. Future studies are needed to 
identify the potential lifestyle and developmental determinants of these T2DM-associated MVPs.
In conclusion, we identified several robust and consistent DNAm markers for incident T2DM. These 
appear to be related to T2DM via glucose and obesity-related pathways that had their effects before 
the collection of baseline samples in these cohort studies, which commenced in midlife. These 
associations indicate several plausible biological mechanisms involved in tissue responses and co-
morbidities of hyperglycemia. 
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Table 1:  Baseline characteristics of participants the EPIC-Norfolk, LOLIPOP and Framingham Heart study samples
EPIC-Norfolk LOLIPOP FHS
Discovery phase Confirmation phase Confirmation phase
Incident T2DM Non-cases Incident T2DM Non-cases
Prevalent 
T2DM Non-cases
N 563 701 1,074 1,590 403 2,204
Sex (F) 474 (84%) 407 (58%) 352 (36.3%) 507 (31.8%) 173 (43.0%) 1245 (56.5%)
Age (years) 61.6 (8.1) 59.1 (9.2) 52.5 (10.2)  49.9 (9.8) 69.3 (8.4) 65.8 (8.9)
Ethnicity European European Indian Asian Indian Asian European European
HbA1c (%) 6.5 (1.3) 5.5 (0.33) 5.77 (0.49) 5.37 (0.48) 6.67 (1.15) % 5.55 (0.27) %
HbA1c (mmol/mol) 47.4 (14.2) 36.2 (3.6) 40 (5.4) 35 (5.2) 49 (12.6) 37 (3)
BMI (kg/m2) 29.2 (4.5) 25.6 (3.6) 28.9 (4.6) 26.7 (3.9) 31.6 (6.2) 27.7 (5.0)
Means (standard deviations) or number (%) are shown.
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Table 2:  Methylation variable positions associated with incident type 2 diabetes at P<1.0E-07 in the EPIC-Norfolk study (N=1,264)
CpG ID Chr Position OR CI 95% P-value FDR Gene name Gene position
cg19693031 1 144152909 0.52 [0.46-0.6] 2.7E-21 1.3E-15 TXNIP 3'UTR
cg06500161 21 42529656 1.65 [1.45-1.89] 6.4E-14 1.5E-08 ABCG1 Body
cg14476101 1 120057515 0.67 [0.59-0.76] 2.8E-10 3.9E-05 PHGDH Body
cg14020176 17 70276580 1.63 [1.4-1.9] 3.3E-10 3.9E-05 SLC9A3R1 3'UTR
cg11024682 17 17670819 1.56 [1.35-1.79] 6.0E-10 5.7E-05 SREBF1 Body
cg06397161 22 38090005 1.51 [1.32-1.73] 4.5E-09 3.3E-04 SYNGR1 Body;TSS200
cg00574958 11 68364198 0.69 [0.61-0.78] 5.2E-09 3.3E-04 CPT1A 5'UTR
cg06235429 11 67129690 1.49 [1.3-1.7] 5.5E-09 3.3E-04 NDUFV1 TSS1500
cg05778424 17 52524507 1.69 [1.42-2.02] 7.4E-09 3.9E-04 AKAP1 5'UTR
cg11376147 11 57017774 0.68 [0.59-0.77] 1.3E-08 6.0E-04 SLC43A1 Body
cg04816311 7 1033176 1.51 [1.31-1.75] 1.7E-08 7.2E-04 C7orf50 Body
cg02711608 19 51979804 0.69 [0.6-0.79] 4.5E-08 1.5E-03 SLC1A5 1stExon;5'UTR
cg08309687 21 34242466 0.68 [0.6-0.78] 4.5E-08 1.5E-03
cg13514042 7 1158728 1.42 [1.25-1.61] 4.5E-08 1.5E-03
cg08994060 10 6254032 0.65 [0.55-0.76] 5.2E-08 1.6E-03 PFKFB3 Body
cg01676795 7 75424284 1.56 [1.33-1.84] 6.5E-08 1.8E-03 POR Body
cg25130381 1 27313308 1.49 [1.29-1.73] 6.7E-08 1.8E-03 SLC9A1 Body
cg11183227 15 89256411 1.49 [1.29-1.72] 7.0E-08 1.8E-03 MAN2A2 Body
Position: by HapMap Build37. OR: odds ratio per +1 standard deviation in methylation intensity. Genes: Gene names in which the CpG falls between 1500bp 
upstream of the transcriptional start site to the end of the 3' UTR as in Illumina's HM450 manifest file.
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Table 3:  Confirmation of the top 18 T2DM-associated MVPs in the LOLIPOP and Framingham Heart studies
 Discovery LOLIPOP Framingham Heart Study*
 Incident T2DM Incident T2DM Prevalent T2DM
CpG ID Chr Gene OR CI 95% OR CI 95% P beta se P
cg19693031 1 TXNIP 0.52 [0.46-0.6] 0.68 [0.62-0.75] 1.2E-14 -2.6E-02 2.7E-03 1.6E-21
cg06500161 21 ABCG1 1.65 [1.45-1.89] 1.44 [1.31-1.58] 2.6E-14 1.5E-02 1.8E-03 7.1E-17
cg14476101 1 PHGDH 0.67 [0.59-0.76] 0.81 [0.75-0.89] 3.0E-06 -1.6E-02 3.6E-03 1.5E-05
cg14020176 17 SLC9A3R1 1.63 [1.4-1.9] 1.14 [1-1.29] 4.3E-02 5.4E-03 1.5E-03 3.9E-04
cg11024682 17 SREBF1 1.56 [1.35-1.79] 1.40 [1.26-1.57] 2.2E-09 8.6E-03 1.6E-03 5.4E-08
cg06397161 22 SYNGR1 1.51 [1.32-1.73] 1.17 [1.06-1.28] 1.1E-03 9.6E-03 2.2E-03 1.6E-05
cg00574958 11 CPT1A 0.69 [0.61-0.78] 0.80 [0.74-0.88] 1.1E-06 -6.7E-03 7.9E-04 4.8E-17
cg06235429 11 NDUFV1 1.49 [1.3-1.7] 1.11 [1-1.24] 5.8E-02 2.4E-03 1.3E-03 6.5E-02
cg05778424 17 AKAP1 1.69 [1.42-2.02] 1.44 [1.21-1.71] 3.5E-05 4.9E-03 1.6E-03 2.5E-03
cg11376147 11 SLC43A1 0.68 [0.59-0.77] 0.85 [0.74-0.97] 1.5E-02 -3.2E-03 1.2E-03 8.4E-03
cg04816311 7 C7orf50 1.51 [1.31-1.75] 1.13 [1-1.27] 4.4E-02 2.0E-02 3.2E-03 8.4E-10
cg02711608 19 SLC1A5 0.69 [0.6-0.79] 0.84 [0.76-0.93] 9.7E-04 -7.9E-03 1.7E-03 2.0E-06
cg08309687 21 - 0.68 [0.6-0.78] 0.82 [0.74-0.91] 1.9E-04 -7.8E-03 3.0E-03 1.0E-02
cg13514042 7 - 1.42 [1.25-1.61] 1.04 [0.94-1.15] 4.4E-01 1.8E-04 1.4E-03 9.0E-01
cg08994060 10 PFKFB3 0.65 [0.55-0.76] 0.81 [0.72-0.92] 6.6E-04 -1.6E-02 2.5E-03 8.5E-10
cg01676795 7 POR 1.56 [1.33-1.84] 1.09 [0.95-1.26] 2.2E-01 9.2E-03 2.4E-03 1.2E-04
cg25130381 1 SLC9A1 1.49 [1.29-1.73] 1.23 [1.09-1.39] 1.2E-03 6.5E-03 1.7E-03 1.7E-04
cg11183227 15 MAN2A2 1.49 [1.29-1.72] 1.08 [0.97-1.2] 1.9E-01 4.6E-03 2.0E-03 2.2E-02
MVPs and individual cells with confirmed association P<0.05 are highlighted in bold.  FHS: T2DM (403 cases, 2,204 controls).  LOLIPOP: (1,074 cases, 
1,590 controls).  OR: odds ratio for T2DM per +1 standard deviation in methylation intensity.
*In FHS, beta indicates difference in percentage DNA methylation intensity between cases and controls, adjusted for age, sex, PC1-3 (calculated from 
methylation data), batch and family structure.
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Table 4:  Analysis of the top 18 T2DM-associated MVPs in non-blood tissues
BLOOD (T2DM EPIC-Norfolk) LIVER FAT MUSCLE
T2D-CONT2D-CON T2D-CON T2D-CON T2D-CON T2D  CON T2D-CON T2D-CON T2D-CON T2D  CON T2D-CON T2D-CON T2D-CON
CpG ID Chr OR P-value Gene lm_coeff P-value Consistent  (mean beta) (mean beta) (mean beta) P-value Consistent  (mean beta) (mean beta) (mean beta) P-value Consistent  
cg19693031 1 0.52 2.7E-21 TXNIP -0.041 0.65 TRUE 0.501 0.499 0.002 0.71 FALSE 0.594 0.634 -0.040 0.02 TRUE
cg06500161 21 1.65 6.4E-14 ABCG1 0.035 0.64 TRUE 0.477 0.439 0.038 0.02 TRUE 0.360 0.349 0.011 0.75 TRUE
cg14476101 1 0.67 2.8E-10 PHGDH 0.080 0.14 FALSE 0.565 0.561 0.004 0.86 FALSE 0.483 0.484 -0.001 0.85 TRUE
cg14020176 17 1.63 3.3E-10 SLC9A3R1 0.065 0.26 TRUE 0.678 0.686 -0.008 0.36 FALSE 0.741 0.748 -0.007 0.52 FALSE
cg11024682 17 1.56 6.0E-10 SREBF1 0.081 0.24 TRUE 0.646 0.640 0.007 0.58 TRUE 0.406 0.391 0.016 0.96 TRUE
cg06397161 22 1.51 4.5E-09 SYNGR1 -0.145 0.07 FALSE 0.501 0.516 -0.015 0.09 FALSE 0.562 0.566 -0.005 0.78 FALSE
cg00574958 11 0.69 5.2E-09 CPT1A 0.059 0.42 FALSE 0.091 0.096 -0.005 0.22 TRUE 0.097 0.103 -0.006 0.33 TRUE
cg06235429 11 1.49 5.5E-09 NDUFV1 -0.037 0.60 FALSE 0.793 0.793 0.001 0.43 TRUE 0.764 0.765 -0.001 0.82 FALSE
cg05778424 17 1.69 7.4E-09 AKAP1 0.019 0.75 TRUE 0.583 0.594 -0.011 0.36 FALSE 0.644 0.648 -0.005 0.64 FALSE
cg11376147 11 0.68 1.3E-08 SLC43A1 0.076 0.15 FALSE 0.301 0.305 -0.005 0.54 TRUE 0.282 0.285 -0.003 0.64 TRUE
cg04816311 7 1.51 1.7E-08 C7orf50 0.026 0.63 TRUE 0.853 0.861 -0.008 0.81 FALSE 0.879 0.885 -0.006 0.35 FALSE
cg02711608 19 0.69 4.5E-08 SLC1A5 0.018 0.72 FALSE 0.245 0.256 -0.011 0.06 TRUE 0.356 0.376 -0.020 0.06 TRUE
cg08309687 21 0.68 4.5E-08 0.017 0.85 FALSE 0.634 0.653 -0.019 0.12 TRUE 0.446 0.445 0.001 0.85 FALSE
cg13514042 7 1.42 4.5E-08 0.130 0.09 TRUE 0.710 0.706 0.003 0.71 TRUE 0.732 0.724 0.007 0.55 TRUE
cg08994060 10 0.65 5.2E-08 PFKFB3 -0.095 0.17 TRUE 0.170 0.175 -0.005 0.86 TRUE 0.154 0.143 0.011 0.55 FALSE
cg01676795 7 1.56 6.5E-08 POR -0.090 0.47 FALSE 0.851 0.852 -0.001 0.86 FALSE 0.890 0.892 -0.002 0.85 FALSE
cg25130381 1 1.49 6.7E-08 SLC9A1 -0.069 0.14 FALSE 0.621 0.610 0.011 0.19 TRUE 0.764 0.776 -0.011 0.40 FALSE
cg11183227 15 1.49 7.0E-08 MAN2A2 -0.105 0.19 FALSE 0.945 0.946 -0.001 0.63 FALSE 0.906 0.910 -0.004 0.40 FALSE
T2D: Type 2 diabetes cases
CON: Controls
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Figure Legend
Figure 1:  Predicted causal effects of DNA methylation on type 2 diabetes
The scatterplot shows the genetic-predicted effects of DNA methylation intensity on risk for Type 2 
diabetes (Y-axis) plotted against observed effect estimates (from the LOLIPOP confirmation phase; 
X-axis) at each of 16 top-hit methylation variable positions (see Table S7). Effect sizes are log-odds 
ratios per 1 unit change in normalised methylation intensity aligned to higher observed odds of Type 2 
diabetes. 
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1Supplementary Tables 1-11
Epigenome-wide association study of incident Type 2 diabetes in a British population: 
EPIC-Norfolk study
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2Table S1. Summary of DNA methylation array data generation and processing across the cohorts
Cohort EPIC-Norfolk LOLIPOP FHS
Sample size 1264 1,074 (incident T2DM)/ 1,590 (controls) 2741
DNA source whole blood whole blood whole blood
Methylation array Illumina HM450k Illumina HM450k Illumina HM450k
normalisation quantile normalisation quantile normalisation DASEN
QC method Ref. 17 Ref. 17 Ref. 19
Statistical model
T2DM status ~ methylation + 
age + sex + estimated white 
blood cell counts + sample plate
T2DM status ~ methylation + control probes + 
bisulfite conversion batch + measured white blood 
cells + imputed white blood cell subsets + 5 PCA 
(corrected for genomic control inflation factor).
Methylation ~ T2DM status + age + sex 
+ white blood cell counts + technical 
covariates + batch effects +BMI
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3Table S2:  Confirmation in EPIC-Norfolk of the 5 MVPs with consistent associations with incident T2DM reported by Chambers et al. (2015)
*These additional two MVPs were reportedly not significantly associated (P>0.05) with T2DM in their European replication samples.
MVPs with confirmed association P<7.1E-03 (=0.05/7) are highlighted.
Chambers et al. 2015 EPIC-Norfolk Study
CpG Chr Position Gene(s) RR (Indian Asians) P (Indian Asians) RR (Europeans) P (Europeans) OR CI 95% P
cg19693031 1 145441552 TXNIP 0·92 (0·91–0·94) 1.0E-13 0·96 (0·94–0·98) 2.50E-05 0.524 [0.46-0.6] 2.7E-21
cg06500161 21 43656587 ABCG1 1·08 (1·06–1·10) 2.2E-13 1·04 (1·02–1·06) 1.2E-04 1.655 [1.45-1.89] 6.4E-14
cg11024682 17 17730094 SREBF1 1·06 (1·04–1·08) 8.4E-09 1·03 (0·95–0·99) 5.4E-03 1.556 [1.35-1.79] 6.0E-10
cg02650017 17 47301614 PHOSPHO1 0·94 (0·92–0·96) 2.1E-09 0·97 (0·95–0·99) 1.2E-03 0.863 [0.76-0.97] 1.8E-02
cg18181703 17 76354621 SOCS3 0·95 (0·93–0·97) 2.1E-07 0·97 (0·95–0·99) 1.6E-03 0.909 [0.81-1.02] 1.2E-01
Reported inconsistent associations  
* cg04999691 7 150027050 C7orf29 0·95 (0·93–0·96) 1.4E-08 1·00 (0·98–1·02) 7.1E-01 0.999 [0.88-1.14] 9.9E-01
* cg09152259 2 128156114 PROC 0·95 (0·93–0·97) 9.3E-08 0·99 (0·97–1·01) 3.2E-01 0.799 [0.71-0.91] 4.2E-04
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4Table S3:  Conditional models for the top 18 MVPs associated with incident T2DM - adjusted for baseline BMI (B), HbA1c (C), BMI & HbA1c (D), in the EPIC-
Norfolk study
Model A:  adjusted for age, sex, estimated cell counts and technical covariates (Discovery).
Model B:  model A + adjustment for baseline BMI.
Model C:  model A + adjustment for baseline HbA1c.
Model D: model A + adjustement for baseline HbA1c and BMI.  
OR:  Odds Ratio per +1 SD in normalised methylation intensity; CI 95%:  95% Confidence Interval; Attentn: % Attenuation in the odds ratio from Model A.
 Model A Model B (n=1260) Model C (n=1262)  Model D (n=1256)  
CpG ID Chr Position Gene OR CI 95% P-value OR CI 95% P-value Attentn. OR CI 95% P-value Attentn. OR CI 95% P-value Attentn.
cg19693031 1 144152909 TXNIP 0.52 [0.46-0.6] 2.7E-21 0.55 [0.47-0.63] 2.5E-16 5% 0.68 [0.57-0.81] 8.5E-06 33% 0.68 [0.57-0.81] 1.9E-05 33%
cg06500161 21 42529656 ABCG1 1.65 [1.45-1.89] 6.4E-14 1.47 [1.27-1.69] 1.2E-07 29% 1.48 [1.25-1.75] 4.5E-06 26% 1.36 [1.13-1.62] 8.0E-04 46%
cg14476101 1 120057515 PHGDH 0.67 [0.59-0.76] 2.8E-10 0.78 [0.68-0.9] 4.4E-04 35% 0.68 [0.58-0.8] 4.1E-06 5% 0.76 [0.64-0.91] 1.9E-03 29%
cg14020176 17 70276580 SLC9A3R1 1.63 [1.4-1.9] 3.3E-10 1.48 [1.26-1.75] 3.6E-06 24% 1.36 [1.11-1.65] 2.4E-03 44% 1.26 [1.02-1.55] 3.1E-02 59%
cg11024682 17 17670819 SREBF1 1.56 [1.35-1.79] 6.0E-10 1.43 [1.23-1.67] 3.4E-06 22% 1.31 [1.08-1.57] 4.7E-03 45% 1.25 [1.03-1.52] 2.4E-02 55%
cg06397161 22 38090005 SYNGR1 1.51 [1.32-1.73] 4.5E-09 1.44 [1.23-1.68] 3.3E-06 14% 1.30 [1.09-1.56] 4.4E-03 41% 1.26 [1.04-1.53] 1.6E-02 49%
cg00574958 11 68364198 CPT1A 0.69 [0.61-0.78] 5.2E-09 0.79 [0.69-0.9] 5.5E-04 31% 0.73 [0.63-0.86] 1.0E-04 14% 0.81 [0.69-0.96] 1.3E-02 39%
cg06235429 11 67129690 NDUFV1 1.49 [1.3-1.7] 5.5E-09 1.38 [1.2-1.6] 1.2E-05 22% 1.32 [1.11-1.57] 1.9E-03 35% 1.25 [1.04-1.5] 1.6E-02 48%
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] 7.4E-09 1.57 [1.3-1.91] 5.1E-06 17% 1.41 [1.12-1.78] 3.6E-03 41% 1.35 [1.06-1.72] 1.6E-02 50%
cg11376147 11 57017774 SLC43A1 0.68 [0.59-0.77] 1.3E-08 0.72 [0.62-0.84] 1.4E-05 14% 0.66 [0.55-0.79] 5.2E-06 -4% 0.68 [0.56-0.82] 6.8E-05 2%
cg04816311 7 1033176 C7orf50 1.51 [1.31-1.75] 1.7E-08 1.47 [1.26-1.72] 1.4E-06 8% 1.18 [0.98-1.43] 7.4E-02 64% 1.19 [0.98-1.44] 8.2E-02 63%
cg02711608 19 51979804 SLC1A5 0.69 [0.6-0.79] 4.5E-08 0.77 [0.67-0.89] 5.5E-04 27% 0.79 [0.66-0.93] 5.0E-03 31% 0.84 [0.7-1.01] 6.3E-02 50%
cg08309687 21 34242466 - 0.68 [0.6-0.78] 4.5E-08 0.75 [0.64-0.87] 1.4E-04 20% 0.79 [0.67-0.95] 1.0E-02 35% 0.86 [0.71-1.03] 1.1E-01 56%
cg13514042 7 1158728 - 1.42 [1.25-1.61] 4.5E-08 1.33 [1.16-1.53] 4.0E-05 20% 1.36 [1.16-1.59] 1.9E-04 15% 1.30 [1.1-1.54] 2.3E-03 28%
cg08994060 10 6254032 PFKFB3 0.65 [0.55-0.76] 5.2E-08 0.67 [0.56-0.79] 4.5E-06 6% 0.73 [0.59-0.89] 2.1E-03 23% 0.74 [0.59-0.91] 5.1E-03 25%
cg01676795 7 75424284 POR 1.56 [1.33-1.84] 6.5E-08 1.48 [1.24-1.77] 1.3E-05 14% 1.34 [1.08-1.67] 7.6E-03 39% 1.28 [1.02-1.61] 3.3E-02 50%
cg25130381 1 27313308 SLC9A1 1.49 [1.29-1.73] 6.7E-08 1.42 [1.22-1.67] 1.0E-05 14% 1.23 [1.02-1.48] 3.2E-02 54% 1.21 [1-1.48] 5.3E-02 57%
cg11183227 15 89256411 MAN2A2 1.49 [1.29-1.72] 7.0E-08 1.42 [1.21-1.66] 1.7E-05 14% 1.18 [0.99-1.42] 6.8E-02 62% 1.16 [0.96-1.41] 1.3E-01 67%
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5Table S4:  Significant gene-set enrichment analysis results for the EWAS result with MAGENTA.
Significance is based on the FDR 75% cut-off. For further details see the original paper (Segrè et al. 2010).
Database Gene Set
Nominal 
GSEA P-
val 75% 
cut-off
FDR 75% 
cut-off
Exp. Genes above 
75% cutoff
Obs. Genes above 
75% cutoff
Ingenuity JAK.Stat.Signaling 3.00E-04 3.90E-03 3 8
Ingenuity Erythropoietin.Signaling 4.00E-04 4.50E-03 4 10
Ingenuity Insulin.Receptor.Signaling 1.17E-04 5.60E-03 9 19
Ingenuity Fc.Epsilon.RI.Signaling 3.00E-04 6.20E-03 4 10
Ingenuity PI3K.AKT.Signaling 1.20E-03 1.03E-02 7 15
Ingenuity T.Cell.Receptor.Signaling 2.10E-03 1.26E-02 8 16
Ingenuity Integrin.Signaling 1.00E-03 1.29E-02 9 18
Ingenuity B.Cell.Receptor.Signaling 2.20E-03 1.32E-02 8 16
Ingenuity Neuregulin.Signaling 2.10E-03 1.56E-02 6 13
Ingenuity IGF-1.Signaling 6.10E-03 2.10E-02 5 10
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6Table S5:  Evaluation of the top 18 T2DM-associated MVPs with glycemic traits in the Framingham Heart Studies and with BMI in Wahl et al., 2017
Direction of methylation: Associations are aligned to T2DM-increasing methylation changes.  MVPs with associations P<0.05 are highlighted in bold.
*Adjusted for age, sex, PC1-3 (calculated from methylation data), batch and family structure.
** Additionally adjusted for BMI.
Fasting glucose (n=2117)* Fasting insulin (n=2151)** HbA1c (n=2156)*
BMI Wahl 
(n=10,261)
CpG ID Chr Gene
Direction of 
methylation beta se p beta se p beta se p beta se p
cg19693031 1 TXNIP Decreasing 7.4E-04 1.2E-04 4.0E-10 3.4E-03 1.5E-03 2.1E-02 1.1E-02 3.9E-03 6.0E-03 -9.8 2.0 1.5E-06
cg06500161 21 ABCG1 Increasing 5.8E-04 7.9E-05 4.6E-13 8.3E-03 9.5E-04 3.9E-18 1.4E-02 2.6E-03 2.0E-07 34.8 2.3 1.7E-53
cg14476101 1 PHGDH Decreasing 8.5E-04 1.6E-04 9.5E-08 5.5E-03 1.9E-03 4.4E-03 -1.4E-03 5.3E-03 7.9E-01 -14.5 1.6 4.1E-20
cg14020176 17 SLC9A3R1 Increasing 6.9E-05 6.7E-05 3.1E-01 2.2E-03 8.4E-04 7.9E-03 7.0E-03 2.2E-03 1.9E-03 17.5 3.0 3.3E-09
cg11024682 17 SREBF1 Increasing 3.5E-04 6.9E-05 6.9E-07 5.4E-03 8.4E-04 1.5E-10 9.6E-03 2.3E-03 3.0E-05 32.5 3.0 3.6E-27
cg06397161 22 SYNGR1 Increasing 8.6E-05 9.7E-05 3.8E-01 3.7E-03 1.2E-03 2.2E-03 6.1E-03 3.2E-03 6.1E-02 13.6 2.2 5.7E-10
cg00574958 11 CPT1A Decreasing 2.6E-04 3.6E-05 4.4E-13 3.2E-03 4.3E-04 4.4E-13 3.6E-03 1.2E-03 2.4E-03 -40.2 3.1 1.4E-38
cg06235429 11 NDUFV1 Increasing 7.5E-05 5.8E-05 1.9E-01 3.2E-04 7.1E-04 6.5E-01 1.5E-03 1.9E-03 4.3E-01 15.5 3.9 8.3E-05
cg05778424 17 AKAP1 Increasing 2.1E-04 7.1E-05 3.5E-03 3.3E-03 8.8E-04 2.1E-04 7.5E-03 2.4E-03 1.6E-03 21.6 2.8 1.2E-14
cg11376147 11 SLC43A1 Decreasing 1.5E-04 5.5E-05 5.8E-03 1.1E-03 6.8E-04 1.2E-01 2.5E-03 1.8E-03 1.7E-01 -25.3 3.0 2.9E-17
cg04816311 7 C7orf50 Increasing 4.8E-04 1.4E-04 6.7E-04 6.2E-03 1.7E-03 3.6E-04 1.8E-02 4.7E-03 1.7E-04 9.3 1.8 1.9E-07
cg02711608 19 SLC1A5 Decreasing 1.7E-04 7.3E-05 2.2E-02 2.8E-03 9.1E-04 2.4E-03 -8.2E-04 2.4E-03 7.3E-01 -17.2 2.4 1.3E-12
cg08309687 21 - Decreasing 6.6E-04 1.3E-04 7.9E-07 6.9E-03 1.7E-03 3.0E-05 1.7E-02 4.4E-03 9.6E-05 -15.2 1.9 9.4E-16
cg13514042 7 - Increasing 1.2E-04 6.3E-05 5.9E-02 8.8E-04 7.7E-04 2.6E-01 2.8E-03 2.1E-03 1.8E-01 14.7 4.4 9.1E-04
cg08994060 10 PFKFB3 Decreasing 3.4E-04 1.1E-04 2.2E-03 4.2E-03 1.4E-03 3.0E-03 9.7E-03 3.8E-03 9.7E-03 -7.2 1.7 1.8E-05
cg01676795 7 POR Increasing 1.6E-04 1.0E-04 1.2E-01 3.1E-03 1.3E-03 1.5E-02 1.3E-02 3.5E-03 1.3E-04 10.7 2.4 7.9E-06
cg25130381 1 SLC9A1 Increasing 1.6E-04 7.6E-05 3.2E-02 3.5E-03 9.4E-04 2.0E-04 6.1E-03 2.6E-03 1.7E-02 14.1 2.5 3.1E-08
cg11183227 15 MAN2A2 Increasing 2.6E-04 9.0E-05 4.4E-03 3.1E-03 1.1E-03 4.9E-03 5.5E-03 3.0E-03 6.4E-02 18.9 2.8 3.0E-11
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7Table S6:  Evaluation of the top 18 T2DM-associated MVPs with cross-sectional differences in DNA methylation intensity between monozygous twin pairs 
discordant for Type 1 diabetes (T1DM).
*Odds ratio for incident T2DM in the discovery EPIC Norfolk study
FDR: false-discovery rate, based on paired T-tests. Delta Beta: Controls minus T1DM 
No T1DM data were available for cg06397161 (SYNGR1) or cg02711608 (SLC1A5)
Monocyte B cell T cell
CpG ID Gene
OR for 
T2DM*
Beta 
Controls
Beta 
T1DM Delta Beta FDR
Beta 
Controls
Beta 
T1DM Delta Beta FDR
Beta 
Controls
Beta 
T1DM Delta Beta FDR
cg19693031 TXNIP 0.52 0.680 0.744 -0.064 2.1E-05 0.886 0.919 -0.033 4.3E-04 0.806 0.803 0.003 7.9E-01
cg06500161 ABCG1 1.65 0.741 0.740 0.001 8.7E-01 0.491 0.481 0.010 3.2E-01 0.705 0.713 -0.009 3.5E-01
cg14476101 PHGDH 0.67 0.658 0.649 0.009 5.3E-01 0.806 0.804 0.002 8.7E-01 0.883 0.883 0.001 9.0E-01
cg14020176 SLC9A3R1 1.63 0.639 0.624 0.015 4.3E-04 0.862 0.854 0.009 8.6E-01 0.905 0.903 0.002 7.9E-01
cg11024682 SREBF1 1.56 0.414 0.405 0.010 2.9E-02 0.504 0.500 0.004 8.6E-01 0.525 0.516 0.009 3.5E-01
cg00574958 CPT1A 0.69 0.032 0.033 -0.001 8.5E-01 0.034 0.032 0.001 8.6E-01 0.136 0.157 -0.021 8.3E-03
cg06235429 NDUFV1 1.49 0.891 0.889 0.002 8.2E-01 0.936 0.934 0.002 8.6E-01 0.942 0.946 -0.004 3.5E-01
cg05778424 AKAP1 1.69 0.087 0.084 0.004 8.2E-01 0.764 0.769 -0.005 8.6E-01 0.929 0.926 0.003 7.9E-01
cg11376147 SLC43A1 0.68 0.304 0.301 0.003 8.2E-01 0.246 0.245 0.001 9.3E-01 0.164 0.165 0.000 9.0E-01
cg04816311 C7orf50 1.51  0.360 0.333 0.026 2.6E-02 0.328 0.333 -0.005 8.6E-01 0.940 0.941 -0.001 7.9E-01
cg08309687 NA 0.68 0.657 0.689 -0.032 4.0E-03 0.634 0.657 -0.022 1.1E-01 0.069 0.067 0.002 7.9E-01
cg13514042 NA 1.42 0.814 0.813 0.001 8.7E-01 0.854 0.850 0.004 8.6E-01 0.912 0.910 0.002 7.9E-01
cg08994060 PFKFB3 0.65 0.090 0.105 -0.015 2.0E-02 0.334 0.377 -0.043 1.2E-05 0.576 0.594 -0.018 4.7E-02
cg01676795 POR 1.56 0.901 0.900 0.001 8.7E-01 0.960 0.963 -0.002 8.6E-01 0.982 0.980 0.002 3.5E-01
cg25130381 SLC9A1 1.49 0.676 0.665 0.011 3.0E-01 0.819 0.817 0.002 8.7E-01 0.436 0.428 0.008 5.1E-01
cg11183227 MAN2A2 1.49 0.981 0.981 -0.001 8.2E-01 0.976 0.975 0.001 8.6E-01 0.983 0.982 0.002 3.5E-01
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8Table S7:  Spearman correlations in DNA methylation intensity between whole blood and liver, pancreas, adipose tissue or muscle at the top 18 T2DM-associated 
MVPs.
Liver and Pancreas samples are from 6 cadaveric samples; Spearman Rho values >=0.5 are highlighted in bold
Fat and muscle samples are from 14 and 16 twin pairs, respectively; correlations at P<0.05 are highlighted in bold
BLOOD (T2DM EPIC-Norfolk) LIVER PANCREAS FAT MUSCLE
CpG ID Chr Gene Rho P-value Rho P-value Rho P-value Rho P-value
cg19693031 1 TXNIP 0.7 0.23 0.8 0.33 -0.2 0.24 0.2 0.25
cg06500161 21 ABCG1 -0.7 0.23 0.2 0.92 0.1 0.68 0.0 0.87
cg14476101 1 PHGDH 0.7 0.23 0.2 0.92 0.2 0.23 -0.1 0.78
cg14020176 17 SLC9A3R1 0.7 0.23 0.8 0.33 0.4 0.05 0.0 0.81
cg11024682 17 SREBF1 0.4 0.52 0.0 1.00 0.5 0.01 0.0 0.79
cg06397161 22 SYNGR1 0.3 0.68 0.0 1.00 0.5 0.01 0.2 0.18
cg00574958 11 CPT1A 0.5 0.45 -0.4 0.75 0.5 0.01 -0.2 0.21
cg06235429 11 NDUFV1 -0.8 0.13 0.4 0.75 0.3 0.08 0.0 0.85
cg05778424 17 AKAP1 -0.5 0.45 -0.8 0.33 0.2 0.20 0.0 0.95
cg11376147 11 SLC43A1 0.7 0.23 0.4 0.75 0.2 0.40 -0.2 0.20
cg04816311 7 C7orf50 0.6 0.35 0.2 0.92 -0.1 0.64 0.1 0.63
cg02711608 19 SLC1A5 1.0 0.02 0.0 1.00 0.2 0.37 -0.1 0.47
cg08309687 21 NA 0.1 0.95 0.2 0.92 0.7 0.0001 0.0 0.95
cg13514042 7 NA -0.5 0.45 0.2 0.92 -0.1 0.76 0.0 0.95
cg08994060 10 PFKFB3 0.0 1.00 -0.4 0.75 0.2 0.24 0.4 0.03
cg01676795 7 POR -0.9 0.08 1.0 0.08 0.2 0.43 -0.2 0.37
cg25130381 1 SLC9A1 -0.3 0.68 0.0 1.00 0.2 0.32 -0.1 0.58
cg11183227 15 MAN2A2 0.7 0.23 0.6 0.42 0.4 0.02 0.1 0.63
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9Table S8:  Individual methQTLs identified in the BIOS-QTL browser for 16 of the 18 T2DM-associated MVPs.
Methylation quantitative trait loci (methQTLs) are SNPs with a genome-wide significant association (FDR< 5%) with any of the 18 T2DM-associated MVPs.  
* aligned to increasing T2DM.
MVP and its observed association with T2DM SNP to Methylation
MVP chr position Gene  OR*MVP-T2DM CI 95% SNP chr position Type A1 A2 Z-score A1-to-MVP P-value
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs1047891 2 211540507 trans A C -8.23 1.93E-16
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs715 2 211543055 trans C T -8 1.20E-15
cg14020176 17 70276580 SLC9A3R1 1.63 [1.4-1.9] rs7529925 1 199007208 trans C T 6.64 3.12E-11
cg11183227 15 89256411 MAN2A2 1.49 [1.29-1.72] rs9790517 4 106084778 trans T C -6.48 9.44E-11
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs2216405 2 211616894 trans G A -6.44 1.20E-10
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs1544196 1 224632782 trans A G -6.43 1.26E-10
cg08309687 21 34242466 1.46 [1.28-1.68] rs6763931 3 141102833 trans A G 5.7 1.23E-08
cg08309687 21 34242466 1.46 [1.28-1.68] rs1991431 3 141133450 trans A G 5.69 1.25E-08
cg08309687 21 34242466 1.46 [1.28-1.68] rs724016 3 141105570 trans G A 5.69 1.25E-08
cg08309687 21 34242466 1.46 [1.28-1.68] rs6440003 3 141094209 trans A G 5.63 1.84E-08
cg00574958 11 68364198 CPT1A 1.45 [1.28-1.64] rs964184 11 116648917 trans G C -5.54 2.99E-08
cg08994060 10 6254032 PFKFB3 1.55 [1.32-1.81] rs6763931 3 141102833 trans A G 5.48 4.30E-08
cg00574958 11 68364198 CPT1A 1.45 [1.28-1.64] rs3741298 11 116657561 trans C T -5.48 4.34E-08
cg08309687 21 34242466 1.46 [1.28-1.68] rs9310736 3 24350811 trans A G -5.48 4.36E-08
cg08994060 10 6254032 PFKFB3 1.55 [1.32-1.81] rs6440003 3 141094209 trans A G 5.46 4.70E-08
cg08994060 10 6254032 PFKFB3 1.55 [1.32-1.81] rs724016 3 141105570 trans G A 5.43 5.72E-08
cg02711608 19 51979804 SLC1A5 1.45 [1.27-1.66] rs4948102 7 56097265 trans C G -5.41 6.25E-08
cg08994060 10 6254032 PFKFB3 1.55 [1.32-1.81] rs1991431 3 141133450 trans A G 5.29 1.23E-07
cg11024682 17 17670819 SREBF1 1.56 [1.35-1.79] rs7701414 5 131585958 trans G A 5.21 1.94E-07
cg11024682 17 17670819 SREBF1 1.56 [1.35-1.79] rs7529925 1 199007208 trans C T -5.15 2.62E-07
cg11183227 15 89256411 MAN2A2 1.49 [1.29-1.72] rs1544196 1 224632782 trans A G -5.15 2.65E-07
cg08994060 10 6254032 PFKFB3 1.55 [1.32-1.81] rs592866 10 6205922 cis A T -41.2 3.27E-310
cg04816311 7 1033176 C7orf50 1.51 [1.31-1.75] rs56048221 7 1092533 cis G A 32.6 4.80E-233
cg14476101 1 120057515 PHGDH 1.50 [1.32-1.7] rs11583993 1 120255370 cis A G -32.2 3.85E-228
cg01676795 7 75424284 POR 1.56 [1.33-1.84] rs10954750 7 75664921 cis C G -22.8 7.21E-115
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cg06397161 22 38090005 SYNGR1 1.51 [1.32-1.73] rs2069235 22 39747780 cis A G -17.5 1.72E-68
cg08309687 21 34242466 1.46 [1.28-1.68] rs8128167 21 35307200 cis C T 17.5 1.92E-68
cg13514042 7 1158728 1.42 [1.25-1.61] rs2949204 7 1200845 cis G A 16.1 4.85E-58
cg06235429 11 67129690 NDUFV1 1.49 [1.3-1.7] rs4244823 11 67361356 cis A G -13.9 1.24E-43
cg14020176 17 70276580 SLC9A3R1 1.63 [1.4-1.9] rs12601504 17 72754829 cis C T 13.5 2.02E-41
cg06397161 22 38090005 SYNGR1 1.51 [1.32-1.73] rs1569499 22 39769818 cis T C -13.4 3.50E-41
cg04816311 7 1033176 C7orf50 1.51 [1.31-1.75] rs12701708 7 1090333 cis T C -12.4 4.25E-35
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs2160115 17 55165612 cis C T -12.1 7.15E-34
cg08309687 21 34242466 1.46 [1.28-1.68] rs2051387 21 35364046 cis A T -10.9 1.22E-27
cg13514042 7 1158728 1.42 [1.25-1.61] rs13226093 7 1168754 cis C T -10.1 8.45E-24
cg11024682 17 17670819 SREBF1 1.56 [1.35-1.79] rs8070432 17 17480474 cis C T 8.92 4.83E-19
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs148596028 17 55210022 cis T C -8.45 2.87E-17
cg14476101 1 120057515 PHGDH 1.50 [1.32-1.7] rs41276626 1 120262112 cis A G 7.59 3.14E-14
cg01676795 7 75424284 POR 1.56 [1.33-1.84] rs239950 7 75581714 cis G A -6.85 7.24E-12
cg08309687 21 34242466 1.46 [1.28-1.68] rs75586969 21 35265459 cis T C -6.64 3.03E-11
cg04816311 7 1033176 C7orf50 1.51 [1.31-1.75] rs7784559 7 1002973 cis A G -6 1.99E-09
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs3094438 17 55188373 cis C G 5.92 3.13E-09
cg14476101 1 120057515 PHGDH 1.50 [1.32-1.7] rs34291690 1 120099137 cis A G 5.34 9.22E-08
cg04816311 7 1033176 C7orf50 1.51 [1.31-1.75] rs13226093 7 1168754 cis C T -5.24 1.64E-07
cg11376147 11 57017774 SLC43A1 1.48 [1.29-1.69] rs2511984 11 57278733 cis T C -5.22 1.76E-07
cg01676795 7 75424284 POR 1.56 [1.33-1.84] rs10954672 7 75481823 cis A G -5.07 3.94E-07
cg01676795 7 75424284 POR 1.56 [1.33-1.84] rs59882870 7 75638421 cis A G -4.74 2.11E-06
cg01676795 7 75424284 POR 1.56 [1.33-1.84] rs7777399 7 75618797 cis T C -4.28 1.88E-05
cg05778424 17 52524507 AKAP1 1.69 [1.42-2.02] rs72843415 17 55163250 cis T C -4.14 3.51E-05
cg06235429 11 67129690 NDUFV1 1.49 [1.3-1.7] rs12799746 11 67246630 cis T C -4.1 4.06E-05
cg08994060 10 6254032 PFKFB3 1.55 [1.32-1.81] rs584797 10 6220496 cis A G 4.06 4.98E-05
cg13514042 7 1158728 1.42 [1.25-1.61] rs55633977 7 1122645 cis T C -4.05 5.14E-05
cg01676795 7 75424284 POR 1.56 [1.33-1.84] rs73145061 7 75353969 cis C G -4.02 5.81E-05
cg25130381 1 27313308 SLC9A1 1.49 [1.29-1.73] rs34079867 1 27407850 cis T C -3.88 0.000105
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Table S9:  Genetically predicted effects of methylation intensity at 16 MVPs on T2DM.
No of methQTLs:  number of methQTLs used in Mendelian Randomization analysis after clumping the SNPs using the R package TwoSampleMR.  The remaining columns 
are generated using the TwoSampleMR package in R. Beta’s indicate the log-odds ratios per 1 unit increase normalised methylation intensity.
Predicted effect Heterogeneity Directional pleiotropy
MVP Gene
No. of 
methQTLs MR model b se P Q df
P-
val Egger_intercept se P
cg08994060 PFKFB3 2 Inverse variance weighted -0.003 0.029 0.92 0 1 1
cg11183227 MAN2A2 2 Inverse variance weighted 0.026 0.038 0.50 0 1 1
cg02711608 SLC1A5 1 Wald ratio 0.018 0.064 0.78
cg08309687 - 3 MR Egger 0.001 0.085 0.99 6.62 1 0.01 -0.01 0.02 0.68
cg08309687 - 3 Inverse variance weighted -0.039 0.034 0.25 4.32 2 0.12
cg14020176 SLC9A3R1 2 Inverse variance weighted -0.027 0.022 0.22 0 1 1
cg06397161 SYNGR1 1 Wald ratio 0.017 0.020 0.40
cg00574958 CPT1A 1 Wald ratio -0.142 0.056 0.01
cg11376147 SLC43A1 1 Wald ratio -0.028 0.067 0.68
cg25130381 SLC9A1 1 Wald ratio -0.150 0.091 0.10
cg11024682 SREBF1 3 MR Egger 0.058 0.054 0.48 0.20 1 0.65 -0.01 0.01 0.45
cg11024682 SREBF1 3 Inverse variance weighted 0.004 0.028 0.88 0.77 2 0.68
cg05778424 AKAP1 3 MR Egger 0.022 0.108 0.87 0.04 1 0.85 -0.01 0.03 0.86
cg05778424 AKAP1 3 Inverse variance weighted -0.002 0.019 0.94 0.04 2 0.98
cg14476101 PHGDH 2 Inverse variance weighted -0.005 0.010 0.65 0 1 1
cg04816311 C7orf50 2 Inverse variance weighted -0.010 0.011 0.39 0 1 1
cg01676795 POR 4 MR Egger -0.013 0.041 0.79 6.18 2 0.05 0.00 0.01 0.89
cg01676795 POR 4 Inverse variance weighted -0.007 0.021 0.73 4.17 3 0.24
cg06235429 NDUFV1 1 Wald ratio 0.017 0.025 0.50
cg13514042 - 1 Wald ratio -0.011 0.021 0.59         
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Table S10:    Mendelian Randomisation tests for determinants of the 18 T2DM-associated MVPs.
Results for the MR associations for the inverse-variance weighted and MR-Egger methods using 2 hour glucose (Saxena et al., 2010), BMI (Locke et al., 2015), fasting 
glucose (Manning et al., 2012), fasting insulin (Scott et al., 2012), fasting insulin adjusted for BMI (Manning et al., 2012), insulin secretion (Prokopenko et al., 2014), insulin 
resistance (Lotta et al., 2016), T2DM status (Morris et al., 2012) and waist hip ratio (Shungin et al., 2015) associated SNPs instrument variables.
IVW MR Heterogenity Egger MR
Potential Determinant MVP
Beta SE p-value Coch Q Coch Q p-value Beta SE p-value intercept
SE 
intercept
p-value 
intercept
2 hour glucose cg00574958 0.06 0.28 0.82 72.31 2.37E-05 -0.33 0.51 0.52 0.01 0.01 0.35
2 hour glucose cg01676795 0.15 0.27 0.58 58.10 1.56E-03 -0.42 0.49 0.39 0.02 0.01 0.09
2 hour glucose cg02711608 0.22 0.20 0.26 5.44 0.71 0.37 0.81 0.65 -0.01 0.06 0.85
2 hour glucose cg04816311 -0.06 0.20 0.76 5.65 0.69 0.69 0.77 0.37 -0.06 0.06 0.31
2 hour glucose cg05778424 0.26 0.18 0.15 4.55 0.80 -0.15 0.70 0.83 0.03 0.06 0.55
2 hour glucose cg06235429 -0.10 0.18 0.57 3.08 0.93 -0.56 0.67 0.40 0.04 0.05 0.44
2 hour glucose cg06397161 0.31 0.20 0.12 5.25 0.73 0.95 0.77 0.22 -0.05 0.06 0.39
2 hour glucose cg06500161 0.02 0.20 0.90 5.39 0.72 0.68 0.78 0.39 -0.05 0.06 0.39
2 hour glucose cg08309687 -0.35 0.19 0.06 4.45 0.81 -0.18 0.76 0.81 -0.01 0.06 0.82
2 hour glucose cg08994060 0.14 0.18 0.42 3.48 0.90 0.69 0.67 0.30 -0.05 0.05 0.36
2 hour glucose cg11024682 -0.17 0.18 0.34 2.88 0.94 -0.76 0.67 0.26 0.05 0.04 0.25
2 hour glucose cg11183227 -0.04 0.18 0.80 3.02 0.93 0.48 0.67 0.48 -0.04 0.04 0.31
2 hour glucose cg11376147 -0.20 0.28 0.48 10.85 0.21 -0.73 1.14 0.52 0.04 0.09 0.63
2 hour glucose cg13514042 0.43 0.18 0.01 1.98 0.98 -0.03 0.67 0.96 0.04 0.04 0.30
2 hour glucose cg14020176 0.36 0.23 0.12 8.81 0.36 0.38 0.96 0.69 0.00 0.08 0.98
2 hour glucose cg14476101 -0.05 0.17 0.78 3.44 0.90 -0.51 0.67 0.44 0.04 0.05 0.46
2 hour glucose cg19693031 -0.31 0.20 0.12 6.26 0.62 -1.37 0.71 0.05 0.09 0.06 0.12
2 hour glucose cg25130381 0.17 0.18 0.33 2.45 0.96 0.69 0.68 0.31 -0.04 0.04 0.27
BMI cg00574958 -0.14 0.17 0.44 176.24 5.1E-08 -0.80 0.42 0.06 0.02 0.01 0.08
BMI cg01676795 -0.18 0.17 0.29 161.10 2.4E-06 -0.04 0.40 0.91 0.00 0.01 0.71
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BMI cg02711608 -0.12 0.17 0.46 161.70 2.1E-06 -0.25 0.41 0.53 0.00 0.01 0.73
BMI cg04816311 -0.19 0.17 0.27 173.55 1.0E-07 -0.43 0.42 0.31 0.01 0.01 0.54
BMI cg05778424 -0.19 0.18 0.29 184.66 5.3E-09 -0.29 0.43 0.50 0.00 0.01 0.79
BMI cg06235429 -0.02 0.17 0.90 157.40 5.8E-06 -0.53 0.41 0.19 0.01 0.01 0.15
BMI cg06397161 0.06 0.17 0.71 155.59 8.8E-06 -0.14 0.41 0.72 0.01 0.01 0.57
BMI cg06500161 -0.15 0.18 0.42 200.01 6.9E-11 -0.05 0.44 0.91 0.00 0.01 0.81
BMI cg08309687 0.03 0.17 0.87 180.81 1.5E-08 -0.37 0.42 0.38 0.01 0.01 0.30
BMI cg08994060 0.12 0.19 0.52 200.93 5.3E-11 0.69 0.45 0.12 -0.02 0.01 0.16
BMI cg11024682 -0.05 0.17 0.76 147.76 5.2E-05 0.06 0.41 0.88 0.00 0.01 0.75
BMI cg11183227 -0.12 0.17 0.48 152.55 1.8E-05 -0.02 0.41 0.96 0.00 0.01 0.78
BMI cg11376147 -0.03 0.17 0.86 175.42 6.4E-08 -0.39 0.42 0.34 0.01 0.01 0.34
BMI cg13514042 -0.38 0.17 0.02 156.25 7.6E-06 -0.93 0.41 0.02 0.02 0.01 0.12
BMI cg14020176 -0.30 0.18 0.08 178.84 2.6E-08 -0.83 0.42 0.05 0.02 0.01 0.17
BMI cg14476101 -0.10 0.17 0.54 145.63 8.4E-05 -0.33 0.40 0.41 0.01 0.01 0.52
BMI cg19693031 0.29 0.17 0.08 137.76 4.3E-04 0.19 0.40 0.64 0.00 0.01 0.77
BMI cg25130381 0.13 0.17 0.44 165.30 8.5E-07 0.62 0.41 0.13 -0.01 0.01 0.19
Fasting glucose cg00574958 0.06 0.28 0.82 72.31 2.4E-05 -0.33 0.51 0.52 0.01 0.01 0.35
Fasting glucose cg01676795 0.15 0.27 0.58 58.10 1.6E-03 -0.42 0.49 0.39 0.02 0.01 0.09
Fasting glucose cg02711608 0.13 0.27 0.64 59.01 1.2E-03 0.15 0.49 0.76 0.00 0.01 0.96
Fasting glucose cg04816311 0.31 0.27 0.26 59.63 1.0E-03 0.31 0.50 0.54 0.00 0.01 0.99
Fasting glucose cg05778424 0.19 0.34 0.57 89.54 7.7E-08 1.22 0.57 0.03 -0.03 0.02 0.03
Fasting glucose cg06235429 -0.15 0.27 0.59 57.27 1.9E-03 -0.18 0.49 0.71 0.00 0.01 0.92
Fasting glucose cg06397161 0.12 0.29 0.68 71.23 3.3E-05 0.26 0.54 0.62 0.00 0.01 0.75
Fasting glucose cg06500161 0.17 0.27 0.52 60.28 8.5E-04 -0.38 0.49 0.44 0.02 0.01 0.14
Fasting glucose cg08309687 -0.15 0.27 0.59 68.39 8.0E-05 -0.31 0.49 0.52 0.01 0.01 0.67
Fasting glucose cg08994060 0.50 0.31 0.11 106.42 1.8E-10 0.29 0.57 0.61 0.01 0.02 0.65
Fasting glucose cg11024682 0.05 0.27 0.86 59.01 1.2E-03 0.21 0.49 0.68 -0.01 0.01 0.69
Fasting glucose cg11183227 -0.04 0.28 0.89 74.19 1.3E-05 -0.41 0.49 0.41 0.01 0.01 0.37
Fasting glucose cg11376147 0.17 0.32 0.60 89.35 8.2E-08 0.17 0.58 0.77 0.00 0.02 1.00
Fasting glucose cg13514042 0.08 0.31 0.79 78.59 3.1E-06 -0.09 0.56 0.87 0.01 0.02 0.70
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Fasting glucose cg14020176 0.07 0.27 0.81 72.23 2.4E-05 -0.15 0.50 0.77 0.01 0.01 0.61
Fasting glucose cg14476101 0.06 0.28 0.82 72.52 2.2E-05 -0.02 0.51 0.97 0.00 0.01 0.85
Fasting glucose cg19693031 0.09 0.27 0.73 62.25 4.9E-04 -0.93 0.49 0.06 0.03 0.01 3.9E-03
Fasting glucose cg25130381 0.19 0.31 0.54 103.78 4.7E-10 -0.15 0.56 0.79 0.01 0.02 0.46
Fasting insulin (adj BMI) cg00574958 0.25 0.68 0.71 32.92 4.8E-03 -3.13 2.94 0.29 0.05 0.04 0.17
Fasting insulin (adj BMI) cg01676795 0.54 0.77 0.49 57.78 6.0E-07 8.83 2.94 0.00 -0.13 0.04 1.0E-03
Fasting insulin (adj BMI) cg02711608 -0.31 0.79 0.69 59.60 3.0E-07 -1.68 3.52 0.63 0.02 0.05 0.69
Fasting insulin (adj BMI) cg04816311 -0.56 0.81 0.49 69.28 6.0E-09 2.37 3.56 0.51 -0.04 0.05 0.40
Fasting insulin (adj BMI) cg05778424 0.19 0.68 0.78 29.63 1.3E-02 1.38 2.95 0.64 -0.02 0.04 0.62
Fasting insulin (adj BMI) cg06235429 -1.01 0.70 0.15 47.01 3.7E-05 0.06 3.13 0.98 -0.02 0.05 0.72
Fasting insulin (adj BMI) cg06397161 0.68 0.68 0.32 44.07 1.1E-04 0.02 3.01 0.99 0.01 0.04 0.82
Fasting insulin (adj BMI) cg06500161 -0.38 0.68 0.58 24.40 0.06 0.89 2.95 0.76 -0.02 0.03 0.56
Fasting insulin (adj BMI) cg08309687 -0.61 0.83 0.46 69.62 5.2E-09 3.63 3.56 0.31 -0.06 0.05 0.22
Fasting insulin (adj BMI) cg08994060 -0.54 0.68 0.42 44.25 1.0E-04 -2.13 2.94 0.47 0.02 0.04 0.58
Fasting insulin (adj BMI) cg11024682 -0.02 0.68 0.97 12.04 0.68 -1.30 2.95 0.66 0.02 0.02 0.41
Fasting insulin (adj BMI) cg11183227 0.06 0.72 0.93 48.31 2.3E-05 5.90 2.95 0.05 -0.09 0.04 0.03
Fasting insulin (adj BMI) cg11376147 0.45 0.68 0.50 40.16 4.3E-04 -0.04 2.95 0.99 0.01 0.04 0.86
Fasting insulin (adj BMI) cg13514042 0.04 0.92 0.96 78.15 1.5E-10 -9.01 3.27 0.01 0.14 0.05 4.5E-03
Fasting insulin (adj BMI) cg14020176 -0.11 0.91 0.90 73.26 1.2E-09 2.14 4.04 0.60 -0.03 0.06 0.57
Fasting insulin (adj BMI) cg14476101 0.18 0.68 0.80 31.53 0.01 -0.64 2.94 0.83 0.01 0.04 0.75
Fasting insulin (adj BMI) cg19693031 -1.75 0.82 0.03 64.11 4.9E-08 -0.42 3.68 0.91 -0.02 0.05 0.71
Fasting insulin (adj BMI) cg25130381 0.45 0.68 0.51 25.93 0.04 1.69 2.95 0.57 -0.02 0.03 0.58
Insulin secretion cg00574958 -0.27 0.18 0.13 15.65 0.55 -0.60 0.47 0.20 0.02 0.03 0.45
Insulin secretion cg01676795 0.10 0.16 0.52 7.56 0.98 0.00 0.42 0.99 0.01 0.02 0.70
Insulin secretion cg02711608 -0.05 0.19 0.81 19.98 0.28 0.02 0.52 0.97 0.00 0.03 0.89
Insulin secretion cg04816311 0.17 0.17 0.31 16.88 0.46 0.61 0.45 0.18 -0.03 0.03 0.30
Insulin secretion cg05778424 -0.05 0.19 0.80 16.72 0.47 -0.03 0.51 0.95 0.00 0.03 0.98
Insulin secretion cg06235429 0.22 0.16 0.17 18.89 0.33 1.14 0.42 0.01 -0.06 0.02 4.6E-04
Insulin secretion cg06397161 -0.13 0.20 0.52 29.53 0.03 0.14 0.54 0.80 -0.02 0.03 0.59
Insulin secretion cg06500161 0.05 0.16 0.78 14.19 0.65 -0.31 0.43 0.47 0.02 0.03 0.37
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Insulin secretion cg08309687 0.02 0.16 0.91 10.09 0.90 0.11 0.42 0.80 -0.01 0.02 0.79
Insulin secretion cg08994060 -0.38 0.21 0.07 26.33 0.07 -0.29 0.55 0.59 -0.01 0.03 0.87
Insulin secretion cg11024682 0.31 0.16 0.06 27.82 0.05 0.75 0.43 0.08 -0.03 0.03 0.26
Insulin secretion cg11183227 0.14 0.16 0.38 12.52 0.77 -0.08 0.42 0.85 0.01 0.03 0.56
Insulin secretion cg11376147 0.00 0.21 1.00 27.54 0.05 -1.02 0.50 0.04 0.07 0.03 0.03
Insulin secretion cg13514042 0.09 0.20 0.64 21.36 0.21 -0.44 0.53 0.41 0.04 0.03 0.28
Insulin secretion cg14020176 -0.13 0.17 0.45 20.05 0.27 0.60 0.42 0.15 -0.05 0.03 0.06
Insulin secretion cg14476101 0.05 0.16 0.76 8.58 0.95 -0.32 0.42 0.45 0.02 0.02 0.15
Insulin secretion cg19693031 -0.03 0.16 0.87 18.43 0.36 1.00 0.42 0.02 -0.07 0.02 9.6E-04
Insulin secretion cg25130381 0.09 0.16 0.58 9.34 0.93 0.44 0.42 0.29 -0.02 0.02 0.27
Insulin resistance cg00574958 -0.91 0.62 0.14 238.85 1.3E-28 0.98 1.91 0.61 -0.02 0.02 0.30
Insulin resistance cg01676795 0.26 0.61 0.66 210.47 1.4E-23 1.37 1.89 0.47 -0.01 0.02 0.54
Insulin resistance cg02711608 -0.58 0.69 0.40 272.93 8.6E-35 -1.14 2.16 0.60 0.01 0.02 0.78
Insulin resistance cg04816311 0.39 0.61 0.52 214.72 2.6E-24 -0.05 1.92 0.98 0.00 0.02 0.81
Insulin resistance cg05778424 0.52 0.59 0.38 159.10 6.1E-15 -0.15 1.83 0.93 0.01 0.02 0.66
Insulin resistance cg06235429 -0.22 0.63 0.73 228.51 9.4E-27 -0.37 1.97 0.85 0.00 0.02 0.93
Insulin resistance cg06397161 0.90 0.70 0.20 311.31 6.2E-42 2.57 2.18 0.24 -0.02 0.02 0.42
Insulin resistance cg06500161 0.44 0.59 0.46 200.51 7.5E-22 1.14 1.83 0.53 -0.01 0.02 0.68
Insulin resistance cg08309687 -0.30 0.61 0.63 210.36 1.5E-23 0.26 1.91 0.89 -0.01 0.02 0.76
Insulin resistance cg08994060 -0.15 0.59 0.80 125.65 8.7E-10 -0.74 1.83 0.69 0.01 0.02 0.68
Insulin resistance cg11024682 0.99 0.59 0.09 206.64 6.6E-23 1.37 1.83 0.45 0.00 0.02 0.82
Insulin resistance cg11183227 -0.01 0.59 0.98 180.48 1.9E-18 -1.12 1.83 0.54 0.01 0.02 0.49
Insulin resistance cg11376147 -0.28 0.59 0.64 205.12 1.2E-22 2.35 1.82 0.20 -0.03 0.02 0.13
Insulin resistance cg13514042 0.52 0.65 0.43 236.40 3.7E-28 -1.72 2.01 0.39 0.02 0.02 0.24
Insulin resistance cg14020176 0.15 0.71 0.83 294.11 1.0E-38 0.28 2.23 0.90 0.00 0.02 0.95
Insulin resistance cg14476101 -0.24 0.59 0.69 178.26 4.5E-18 0.69 1.82 0.71 -0.01 0.02 0.57
Insulin resistance cg19693031 -1.33 0.73 0.07 304.97 9.5E-41 -2.42 2.28 0.29 0.01 0.02 0.61
Insulin resistance cg25130381 1.41 0.59 0.02 189.18 6.5E-20 1.25 1.83 0.50 0.00 0.02 0.92
Type 2 diabetes cg00574958 -0.04 0.06 0.56 22.03 1.00 -0.07 0.15 0.66 0.00 0.01 0.83
Type 2 diabetes cg01676795 0.10 0.06 0.11 22.89 0.99 0.01 0.15 0.94 0.01 0.02 0.50
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Type 2 diabetes cg02711608 0.07 0.07 0.35 25.51 0.98 0.01 0.17 0.95 0.01 0.02 0.70
Type 2 diabetes cg04816311 0.03 0.06 0.59 21.60 1.00 0.01 0.15 0.95 0.00 0.01 0.84
Type 2 diabetes cg05778424 0.08 0.06 0.17 17.59 1.00 0.05 0.14 0.71 0.00 0.01 0.77
Type 2 diabetes cg06235429 0.01 0.06 0.83 22.21 0.99 0.05 0.14 0.73 0.00 0.01 0.77
Type 2 diabetes cg06397161 -0.03 0.06 0.69 24.58 0.99 -0.06 0.15 0.67 0.00 0.01 0.78
Type 2 diabetes cg06500161 0.06 0.06 0.34 20.50 1.00 0.19 0.14 0.17 -0.02 0.01 0.28
Type 2 diabetes cg08309687 -0.08 0.06 0.18 18.68 1.00 -0.22 0.14 0.12 0.02 0.01 0.26
Type 2 diabetes cg08994060 0.08 0.07 0.25 27.00 0.96 0.30 0.16 0.06 -0.02 0.02 0.13
Type 2 diabetes cg11024682 0.00 0.07 0.95 27.30 0.96 0.05 0.15 0.72 -0.01 0.02 0.67
Type 2 diabetes cg11183227 0.01 0.06 0.92 19.87 1.00 0.07 0.14 0.62 -0.01 0.01 0.60
Type 2 diabetes cg11376147 -0.03 0.08 0.66 30.77 0.90 -0.03 0.18 0.86 0.00 0.02 0.98
Type 2 diabetes cg13514042 -0.07 0.08 0.38 33.15 0.83 -0.01 0.18 0.95 -0.01 0.02 0.72
Type 2 diabetes cg14020176 0.11 0.06 0.08 23.23 0.99 0.32 0.14 0.03 -0.02 0.01 0.11
Type 2 diabetes cg14476101 -0.03 0.06 0.61 18.91 1.00 0.19 0.14 0.18 -0.02 0.01 0.06
Type 2 diabetes cg19693031 -0.08 0.07 0.28 26.34 0.97 -0.02 0.16 0.91 -0.01 0.02 0.69
Type 2 diabetes cg25130381 0.01 0.06 0.91 16.17 1.00 0.13 0.14 0.37 -0.01 0.01 0.27
WHR (adj. BMI) cg00574958 -0.07 0.26 0.78 67.13 1.8E-03 -1.28 1.31 0.33 0.03 0.04 0.34
WHR (adj. BMI) cg01676795 0.02 0.26 0.93 65.34 2.8E-03 1.14 1.31 0.38 -0.03 0.04 0.38
WHR (adj. BMI) cg02711608 -0.01 0.28 0.98 70.11 8.2E-04 -1.28 1.39 0.35 0.04 0.04 0.35
WHR (adj. BMI) cg04816311 -0.25 0.25 0.31 61.98 0.01 1.29 1.22 0.29 -0.04 0.03 0.20
WHR (adj. BMI) cg05778424 0.00 0.24 0.99 49.18 0.09 -0.02 1.20 0.99 0.00 0.03 0.99
WHR (adj. BMI) cg06235429 0.15 0.24 0.53 38.27 0.41 -1.38 1.21 0.25 0.04 0.03 0.10
WHR (adj. BMI) cg06397161 0.09 0.24 0.70 59.73 0.01 -0.40 1.20 0.74 0.01 0.03 0.68
WHR (adj. BMI) cg06500161 0.09 0.24 0.70 56.91 0.02 -1.06 1.20 0.38 0.03 0.03 0.31
WHR (adj. BMI) cg08309687 -0.08 0.25 0.73 59.58 0.01 0.19 1.25 0.88 -0.01 0.03 0.82
WHR (adj. BMI) cg08994060 0.15 0.25 0.55 61.49 0.01 -1.44 1.22 0.24 0.04 0.03 0.19
WHR (adj. BMI) cg11024682 0.13 0.24 0.60 57.59 0.02 1.39 1.20 0.25 -0.04 0.03 0.28
WHR (adj. BMI) cg11183227 -0.09 0.28 0.76 78.04 9.3E-05 -0.05 1.44 0.97 0.00 0.04 0.98
WHR (adj. BMI) cg11376147 0.16 0.24 0.51 53.07 0.04 -1.70 1.20 0.16 0.05 0.03 0.09
WHR (adj. BMI) cg13514042 -0.17 0.24 0.48 52.92 0.04 0.82 1.20 0.50 -0.03 0.03 0.40
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WHR (adj. BMI) cg14020176 -0.12 0.24 0.62 52.57 0.05 1.47 1.21 0.22 -0.04 0.03 0.16
WHR (adj. BMI) cg14476101 0.10 0.24 0.68 37.83 0.43 0.29 1.20 0.81 -0.01 0.03 0.84
WHR (adj. BMI) cg19693031 -0.28 0.24 0.24 57.56 0.02 -2.27 1.20 0.06 0.06 0.03 0.08
WHR (adj. BMI) cg25130381 0.35 0.24 0.15 45.72 0.15 0.65 1.21 0.59 -0.01 0.03 0.77
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Table S11:  Gene annotations for the top 18 T2DM-associated MVPs.
MVP (CpG ID)Chr Position P-value Gene Gene position Full gene name Gene function Associated disorders 
cg19693031 1 1441529092.7E-21 TXNIP 3'UTR thioredoxin 
interacting protein
The encoded protein inhibits the antioxidative function of 
thioredoxin resulting in the accumulation of reactive oxygen 
species and cellular stress. This protein also regulates cellular 
metabolism and endoplasmic reticulum (ER) stress, and may also 
function as a tumor suppressor.
cg06500161 21 42529656 6.4E-14 ABCG1 Body ATP-binding 
cassette, sub-family 
G (WHITE), member 
1
The encoded protein is a member of the  White subfamily of ATP-
binding cassette (ABC) transporters, and is involved in macrophage 
cholesterol and phospholipids transport, and may regulate cellular 
lipid homeostasis in other cell types.
Tangier disease: Characterized by low levels of 
high-density lipoprotein cholesterol (HDL) in the 
blood and accordingly with moderately increased risk 
of cardiovascular disease.
Autosomal Recessive Nonsyndromic Deafness
cg14476101 1 1200575152.8E-10 PHGDH Body phosphoglycerate 
dehydrogenase
The encoded enzyme is involved in the early steps of L-serine 
synthesis in animal cells. L-serine is required for D-serine and 
other amino acid synthesis. 
Neu-Laxova Syndrome 1: An autosomal recessive 
lethal multiple malformation syndrome.
Phosphoglycerate Dehydrogenase Deficiency: 
characterized by microcephaly; impaired 
development of physical reactions, movements, and 
speech (psychomotor retardation); and recurrent 
seizures (epilepsy). 
cg14020176 17 70276580 3.3E-10SLC9A3R1 3'UTR solute carrier family 
9, subfamily A 
(NHE3, cation 
proton antiporter 3), 
member 3 regulator 1
Encodes a sodium/hydrogen exchanger regulatory cofactor, which 
regulates: the cystic fibrosis transmembrane conductance regulator, 
and G-protein coupled receptors such as the beta2-adrenergic 
receptor and the parathyroid hormone 1 receptor. Interacts with 
proteins that function as linkers between integral membrane and 
cytoskeletal proteins. 
Nephrolithiasis/osteoporosis, hypophosphatemic, 
2: Characterized by decreased renal phosphate 
absorption, renal phosphate wasting, 
hypophosphatemia, hyperphosphaturia, 
hypercalciuria, nephrolithiasis and osteoporosis. 
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cg11024682 17 17670819 6.0E-10 SREBF1 Body sterol regulatory 
element binding 
transcription factor 1 
[alias: sterol 
regulatory element 
binding protein 1; 
SREBP1
Encodes a transcription factor that binds to the sterol regulatory 
element-1 (SRE1), which is a decamer flanking the low density 
lipoprotein receptor gene and some genes involved in sterol 
biosynthesis.  SREBP1 and SREBP2 (600481) are structurally 
related proteins that control cholesterol homeostasis by stimulating 
transcription of sterol-regulated genes. 
This gene is located within the Smith-Magenis 
syndrome region (a developmental disorder 
characterised by  intellectual disability, delayed 
speech and language skills, distinctive facial features, 
sleep disturbances, and behavioral problems).
cg06397161 22 38090005 4.5E-09 SYNGR1 Body;TSS200 synaptogyrin 1 Encodes an integral membrane protein associated with presynaptic 
vesicles in neuronal cells. The exact function is unclear, but may 
function in synaptic plasticity.
cg00574958 11 68364198 5.2E-09 CPT1A 5'UTR carnitine 
palmitoyltransferase 
1A (liver)
Initiates mitochondrial oxidation of long-chain fatty acids. CPT I is 
the key enzyme in the carnitine-dependent transport across the 
mitochondrial inner membrane. Its deficiency results in a decreased 
rate of fatty acid beta-oxidation.
CPT deficiency, hepatic, type IA: An autosomal 
recessive metabolic disorder of long-chain fatty acid 
oxidation characterized by severe episodes of 
hypoketotic hypoglycemia usually occurring after 
fasting or illness.
cg06235429 11 67129690 5.5E-09 NDUFV1 TSS1500 NADH 
dehydrogenase 
(ubiquinone) 
flavoprotein 1, 
51kDa
Encodes a subunit of mitochondrial NADH:ubiquinone 
oxidoreductase complex I; a large complex that liberates electrons 
from NADH and channels them to ubiquinone. This subunit carries 
the NADH-binding site as well as flavin mononucleotide (FMN)- 
and Fe-S-biding sites. 
Mitochondrial Complex I Deficiency: The most 
common enzymatic defect of the oxidative 
phosphorylation disorders. It causes a wide range of 
clinical disorders, including myopathies, 
encephalomyopathies, and neurodegenerative 
disorders. 
cg05778424 17 52524507 7.4E-09 AKAP1 5'UTR A kinase (PRKA) 
anchor protein 1
The encoded protein binds to type I and type II regulatory subunits 
of  protein kinase A (PKA) and anchors them to the mitochondrion. 
This protein is speculated to be involved in the cAMP-dependent 
signal transduction pathway. 
cg11376147 11 57017774 1.3E-08 SLC43A1 Body solute carrier family 
43, member 1
Member of the system L family of plasma membrane carrier 
proteins that transports large neutral amino acids
cg04816311 7 1033176 1.7E-08 C7orf50 Body chromosome 7 open 
reading frame 50 
(194 aa)
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cg02711608 19 51979804 4.5E-08 SLC1A5 1stExon;5'UTR;Bodysolute carrier family 
1 (neutral amino acid 
transporter), member 
5 (541 aa)
Encodes a sodium-dependent neutral amino acid transporter that 
can act as a receptor for RD114/type D retrovirus 
cg08309687 21 34242466 4.5E-08 - -
cg13514042 7 1158728 4.5E-08 - -
cg08994060 10 6254032 5.2E-08 PFKFB3 Body 6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 3
The encoded protein catalyses the synthesis and degradation of 
fructose-2,6-bisphosphate, a regulatory molecule that controls 
glycolysis in eukaryotes. It regulates cyclin-dependent kinase 1, 
linking glucose metabolism to cell proliferation and survival in 
tumor cells. 
cg01676795 7 75424284 6.5E-08 POR Body P450 (cytochrome) 
oxidoreductase
Encodes an endoplasmic reticulum membrane oxidoreductase with 
an FAD-binding domain and a flavodoxin-like domain. The protein 
binds two cofactors, FAD and FMN, which allow it to donate 
electrons directly from NADPH to all microsomal P450 enzymes. 
Antley-Bixler syndrome with genital anomalies 
and disordered steroidogenesis: a rare 
craniosynostosis syndrome characterized by 
radiohumeral synostosis. Other features include 
midface hypoplasia, choanal stenosis or atresia, 
multiple joint contractures, visceral anomalies 
(genitourinary system), and impaired steroidogenesis 
(specific to POR mutations). Disordered 
steroidogenesis due to cytochrome P450 
oxidoreductase: A rare variant of congenital adrenal 
hyperplasia, due to apparent combined deficiency of 
P450C17 and P450C21 and accumulation of steroid 
metabolites. Affected girls are born with ambiguous 
genitalia, indicating intrauterine androgen excess. 
After birth, however, virilization does not progress 
and amounts of circulating androgens are low or 
normal. Affected boys are sometimes born 
undermasculinized.
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cg25130381 1 27313308 6.7E-08 SLC9A1 Body solute carrier family 
9, subfamily A 
(NHE1, cation 
proton antiporter 1), 
member 1
Encodes a Na+/H+ antiporter, a plasma membrane transporter that 
is expressed in the kidney and intestine. Regulates pH homeostasis, 
cell migration and cell volume. 
Lichtenstein-Knorr syndrome: An autosomal 
recessive neurologic disorder characterized by 
postnatal onset of severe progressive sensorineural 
hearing loss and progressive cerebellar ataxia. 
Myocardial Stunning: A state when some section of 
the myocardium (corresponding to area of a major 
coronary occlusion) shows a form of contractile 
abnormality. 
cg11183227 15 89256411 7.0E-08 MAN2A2 Body mannosidase, alpha, 
class 2A, member 2
The encoded protein catalyzes the first committed step in the 
biosynthesis of complex N-glycans. It controls conversion of high 
mannose to complex N-glycans; the final hydrolytic step in the N-
glycan maturation pathway.
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